HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 Linux 18NOV21:22:15:1518NOV21:22:15:15 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS ADDV SASDATA 9.4 Linux 18NOV21:22:15:1518NOV21:22:15:15 HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000006600000000000000000000 STUDYID Study Identifier USUBJID Unique Subject Identifier DOMAIN Domain Abbreviation SUBJID Subject Identifier for the Study SITEID Study Site Identifier (AGE Age ,SEX Sex 4)RACE Race 5 TRTSDT Date of First Exposure to Treatment DATE ^ TRTEDT Date of Last Exposure to Treatment DATE f ARM Description of Planned Arm n ARMCD Planned Arm Code  ACTARM Description of Actual Arm  ACTARMCDActual Arm Code TRT01P Planned Treatment for Period 01 TRT01A Actual Treatment for Period 01 TRT01PN Planned Treatment for Period 01 (N) TRT01AN Actual Treatment for Period 01 (N)  AGEGR1 Pooled Age Group 1 AGEGR1N Pooled Age Group 1 (N) DVSEQ Sequence Number  DVSPID Sponsor-Defined Identifier DVTERM Protocol Deviation Term  2DVTERM1 Protocol Deviation Term 1 DVDECOD Protocol Deviation Coded Term EPOCH Epoch 1ACTSITE Actual Site of Deviation Occurrence E!DESGTOR Visit Designator ICAPE Confirmed Analysis Population Exclusion j DVCAT Category for Protocol Deviation { DVSTDTC Start Date/Time of Deviation  DVSTDY Study Day of Start of Deviation !ASTDT Analysis Start Date DATE "PREFL Pre-treatment Flag #TRPFL On Treatment Flag $RANDFL Randomized Population Flag %PHASE Study Phase &PHASEN Study Phase (N) 'COHORT Cohort Group (COHORTN Cohort Group (N) )DOSALVL Actual Dosing Level *DOSALVLNActual Dosing Level (N) +DOSPLVL Planned Dosing Level ,DOSPLVLNPlanned Dosing Level (N) -DS3KFL FU to 6MPD2 .AGEGR3N Pooled Age Group 3 (N) /AGEGR3 Pooled Age Group 3 0AGEGR4N Pooled Age Group 4 (N)  1AGEGR4 Pooled Age Group 4 2HIVFL HIV Positive Subjects Flag 3AGETR01 Age at Vaccination 01 4TRTSDTM Datetime of First Exposure to Treatment DATETIME 5TRTEDTM Datetime of Last Exposure to Treatment DATETIME 6TR01SDTMDatetime of First Exposure in Period 01 DATETIME 7TR01EDTMDatetime of Last Exposure in Period 01 DATETIME  8TR02SDTMDatetime of First Exposure in Period 02 DATETIME 9TR02EDTMDatetime of Last Exposure in Period 02 DATETIME $:VAX101 Vaccination 01 %$;VAX102 Vaccination 02 I$VAX202 Vaccination 04 ?VAX20U Vaccination Unplanned in Period 02 @VAX20UDTVaccination Date Unplanned in Period 02 DATE AUNBLNDDTTreatment Unblinded Date DATE BSAFFL Safety Population Flag  HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 C4591001C4591001 1005 10051317DV100513171005AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z9W1BYUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1005Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr^Hr|xHr^Hr|x..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051328DV100513281005AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z9W1F3Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1005Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr^Hr{Hr^Hr{..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051339DV100513391005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEAMG1Other Informed Consent Informed Consent FOLLOW-UP 1005Consent NO Non-Important2021-03-04BDWG YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsLHr`Hr{Hsr|pHsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051339DV100513391005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z9W1F6Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1005Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsLHr`Hr{Hsr|pHsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051339DV100513391005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XU5CQNProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-06-09BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsLHr`Hr{Hsr|pHsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051413DV100514131005AMWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1USCBW1Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1005Potential ReVax Initial Contact NO Non-Important2021-04-01BmDWc YYPhase 3A@ . . .Y. A12-15 YearsNAHr(HrHr(Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWcYC4591001C4591001 1005 10051414DV100514141005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OT8117Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1005V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrEHsHrEHrHs}"tHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051414DV100514141005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBFVLProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrEHsHrEHrHs}"tHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051414DV100514141005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YY0VDAVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-06-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrEHsHrEHrHs}"tHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051417DV100514171005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZGA15PVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-08-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsFHrHrŅHsƶxHsFPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051419DV100514191005AFWHITE DVDWTPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OT811BVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1005V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr%Hs"(Hr%HrHsf\Hs"(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1005 10051419DV100514191005AFWHITE DVDWTPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UEHGUJOther Informed Consent Informed Consent OPEN LABEL TREATMENT1005Consent NO Non-Important2021-02-24BGDW? YYPhase 3A@ . . .N. A12-15 YearsNAHr%Hs"(Hr%HrHsf\Hs"(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1005 10051419DV100514191005AFWHITE DVDWTPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XK5AREVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1005COVID_A1 NO Non-Important2021-06-02BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr%Hs"(Hr%HrHsf\Hs"(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1005 10051420DV100514201005AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZH24PKNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK8 NO Non-Important2021-03-31BjDWb YYPhase 3A@ . . .Y. A12-15 YearsNAHr$(HrHr$(Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051420DV100514201005AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1VNE4OGVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK10 NO Non-Important2021-04-14BxDWp YYPhase 3A@ . . .Y. A12-15 YearsNAHr$(HrHr$(Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051420DV100514201005AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZHJ095Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1005SSWAB_WEEK22 NO Non-Important2021-07-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr$(HrHr$(Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051420DV100514201005AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1Z70K1JVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1005V4_MONTH6_L NO Non-Important2021-07-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr$(HrHr$(Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051421DV100514211005AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBFVOProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHru0HsϤHru0Hr!Hss HsϤPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051421DV100514211005AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z9VJW3Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1005V103_MONTH1 NO Non-Important2021-07-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHru0HsϤHru0Hr!Hss HsϤPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051422DV100514221005AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z9VJW6Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1005V103_MONTH1 NO Non-Important2021-07-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrwHshHrwHr"XHssHHshPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051424DV100514241005AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OTC10GVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1005V2_VAX2_L NO Non-Important2021-01-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHroHrDHroHrD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051424DV100514241005AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1SZFK08Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005V202_SURVEIL_SWAB|637848674981060NO Non-Important2021-03-19B\DWV YYPhase 3A@ . . .Y. A12-15 YearsNAHroHrDHroHrD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051424DV100514241005AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1VIS4UEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005POT_COVID_CONVA|640515884311050 NO Non-Important2021-04-16BxDWr YYPhase 3A@ . . .Y. A12-15 YearsNAHroHrDHroHrD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051425DV100514251005AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZH24PNNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK6 NO Non-Important2021-04-03BkDWe YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrCHrLHrC..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051425DV100514251005AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZHUSS7Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK8 NO Non-Important2021-04-09BqDWk YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrCHrLHrC..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1SSTN91Nasal swab collected at a visit where it was not required Laboratory VACCINATION 1005COVID A NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrzDHsHrzDHr%PHsrYHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OTC0WAProcedure not performed as part of vital signs. Procedures/Tests VACCINATION 1005V2_VAX2_L NO Non-Important2021-01-08BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrzDHsHrzDHr%PHsrYHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1RVVF3JVisit conducted when not required per protocol Visit Schedule VACCINATION 1005COVID_A1 NO Non-Important2021-02-04B.DW+ YYPhase 3A@ . . .N. A12-15 YearsNAHrzDHsHrzDHr%PHsrYHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R54FU9Lab performed out of window Laboratory FOLLOW-UP 1005SSWAB_WEEK4 NO Non-Important2021-03-11BQDWN YYPhase 3A@ . . .N. A12-15 YearsNAHrzDHsHrzDHr%PHsrYHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1RVVUHHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK4 NO Non-Important2021-03-11BQDWN YYPhase 3A@ . . .N. A12-15 YearsNAHrzDHsHrzDHr%PHsrYHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051427DV100514271005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XRTK89Procedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrzDHsHrzDHr%PHsrYHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051431DV100514311005AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1UEIK9LOther Informed Consent Informed Consent FOLLOW-UP 1005Consent NO Non-Important2021-02-09B2DW0 YYPhase 3A@ . . .Y. A12-15 YearsNAHrpHr̈́HrpHr̈́..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051438DV100514381005AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBFVRProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrLHs!HrLHrͫHsjHHs!Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051445DV100514451005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZH24PQNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK8 NO Non-Important2021-04-14BrDWp YYPhase 3A@ . . .N. A12-15 YearsNAHr8HsLHr8HrzTHs~HsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051445DV100514451005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZHUSSBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK10 NO Non-Important2021-04-22BzDWx YYPhase 3A@ . . .N. A12-15 YearsNAHr8HsLHr8HrzTHs~HsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051445DV100514451005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZH2CQFNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK12 NO Non-Important2021-05-11BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr8HsLHr8HrzTHs~HsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051445DV100514451005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZHUSSEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK14 NO Non-Important2021-05-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr8HsLHr8HrzTHs~HsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051445DV100514451005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBFVUProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr8HsLHr8HrzTHs~HsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051445DV100514451005AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Y8SL8EProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-06-16BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr8HsLHr8HrzTHs~HsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051447DV100514471005AFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS2TLKOther Informed Consent Informed Consent VACCINATION 1005Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHr$`HrDHr$`HrD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051447DV100514471005AFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS2TLQOther Informed Consent Informed Consent VACCINATION 1005Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHr$`HrDHr$`HrD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051448DV100514481005AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS2TM2Other Informed Consent Informed Consent VACCINATION 1005Consent NO Non-Important2021-01-11ADW YYPhase 3A@ . . .N. A12-15 YearsNAHrCHsHrCHrHs~HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051448DV100514481005AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1UEIVHJOther Informed Consent Informed Consent FOLLOW-UP 1005Consent NO Non-Important2021-03-01B2DWD YYPhase 3A@ . . .N. A12-15 YearsNAHrCHsHrCHrHs~HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051448DV100514481005AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZH2CQJNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1005SSWAB_WEEK4 NO Non-Important2021-04-02BRDWd YYPhase 3A@ . . .N. A12-15 YearsNAHrCHsHrCHrHs~HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051448DV100514481005AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1UIIRQ1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK6 NO Non-Important2021-04-05BUDWg YYPhase 3A@ . . .N. A12-15 YearsNAHrCHsHrCHrHs~HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051448DV100514481005AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YW5EXQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1005Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrCHsHrCHrHs~HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051450DV100514501005AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WTN7QNVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1005SSWAB_WEEK10 NO Non-Important2021-04-26BjDW| YYPhase 3A@ . . .N. A12-15 YearsNAHr^HsmxHr^HrPHs{<HsmxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051450DV100514501005AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBFW7Procedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V101_VAX3 NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr^HsmxHr^HrPHs{<HsmxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051450DV100514501005AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y8SL8JProcedure not performed by a medically qualified individual at specified visits Procedures/Tests OPEN LABEL TREATMENT1005V102_VAX4 NO Non-Important2021-06-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr^HsmxHr^HrPHs{<HsmxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1005 10051451DV100514511005AFWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OTTAVCProcedure/Test not performed per protocol Procedures/Tests SCREENING 1005V1_DAY1_VAX1_L NO Non-Important2021-01-11DWYNYPhase 3A@ . . .Y. A12-15 YearsNAHrͪ`HrHrͪ`Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061183DV100611831006AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OT811HVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-07B'DW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs,HrHr̐Hsv/Hs,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061183DV100611831006AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OS305PVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-07B'DW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs,HrHr̐Hsv/Hs,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061183DV100611831006AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1POJ18NProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1006V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-09BHDW0 YYPhase 3A@ . . .N. A12-15 YearsNAHrHs,HrHr̐Hsv/Hs,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061190DV100611901006AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1XOV7IRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK4 NO Non-Important2021-04-24BDWz YYPhase 3A@ . . .Y. A12-15 YearsNAHrM0Hr8HrM0Hr8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061190DV100611901006AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM22LNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1006SSWAB_WEEK6 NO Non-Important2021-05-12BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrM0Hr8HrM0Hr8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061190DV100611901006AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YCOMHGVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-05-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrM0Hr8HrM0Hr8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061201DV100612011006AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z4PJFHVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006V4_MONTH6_L NO Non-Important2021-07-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrxHr`HrxHr`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061203DV100612031006AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OSO0CLVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1006V2_VAX2_L NO Non-Important2020-12-22BDV YYPhase 3A@ . . .Y. A12-15 YearsNAHrXHr׸HrXHr׸..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061203DV100612031006AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1YCQC4RVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK6 NO Non-Important2021-05-03BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrXHr׸HrXHr׸..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061203DV100612031006AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZMMT2FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-05-27BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrXHr׸HrXHr׸..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061209DV100612091006AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZMMT2JVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-05-25BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr\HrHr\Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061214DV100612141006AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZHUT27Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK8 NO Non-Important2021-05-03BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrSHsHrSHrZHssݤHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061214DV100612141006AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XNGGW5Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006COVID_A1 NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrSHsHrSHrZHssݤHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061214DV100612141006AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YNZMAVVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-06-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrSHsHrSHrZHssݤHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061219DV100612191006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORCDBKVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1006V2_VAX2_L NO Non-Important2020-12-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrtHsHrtHrSHsoHHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061219DV100612191006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y29BS2Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006COVID_A1 NO Non-Important2021-06-11BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrtHsHrtHrSHsoHHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061219DV100612191006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZMMT2MVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK6 NO Non-Important2021-06-11BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrtHsHrtHrSHsoHHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061219DV100612191006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZCT7K7Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-07-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrtHsHrtHrSHsoHHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061224DV100612241006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZMMT8JVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-07-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HHrHr=HHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061224DV100612241006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1Z6G6W8Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006V4_MONTH6_L NO Non-Important2021-07-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HHrHr=HHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061230DV100612301006AFMULTIPLE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OVP24TNasal swab not collected for the visit where it is required Laboratory VACCINATION 1006V2_VAX2_L NO Non-Important2020-12-31BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrpHr0HrpHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061230DV100612301006AFMULTIPLE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZQO1UVNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1006COVID_A NO Non-Important2021-08-10BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrpHr0HrpHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061231DV100612311006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZHUT2AVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK10 NO Non-Important2021-05-26BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHr<HrLHr<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061232DV100612321006AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZHUT2DVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK4 NO Non-Important2021-04-13BDWo YYPhase 3A@ . . .N. A12-15 YearsNAHrHs<HrHrgHss@Hs<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061233DV100612331006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OT811QVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1006V2_VAX2_L NO Non-Important2020-12-29BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsxHrHrgHss|HsxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061241DV100612411006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YV6XRJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-06-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061247DV100612471006AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PAG6XISerology sample not collected Laboratory FOLLOW-UP 1006V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-28B2DW$ YYPhase 3A@ . . .N. A12-15 YearsNAHr^HsSHr^Hr`Hsn`HsSPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061247DV100612471006AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZH10SVVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1006V103_MONTH1 NO Non-Important2021-07-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr^HsSHr^Hr`Hsn`HsSPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061249DV100612491006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZMMT8MVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHHrHrHHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061250DV100612501006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y55S2VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK6 NO Non-Important2021-05-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrIdHs HrIdHrHsv PHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061250DV100612501006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YY0VDNVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-06-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrIdHs HrIdHrHsv PHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061254DV100612541006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1P85LFLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006COVID_A1 NO Non-Important2021-02-02B6DW) YYPhase 3A@ . . .Y. A12-15 YearsNAHrrHrHrrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061256DV100612561006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZMMT8SVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK6 NO Non-Important2021-05-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061256DV100612561006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZMMT8PVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-12BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061258DV100612581006AMNATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERDVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZMN4C1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-24BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr$Hr!\Hr$Hr!\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061259DV100612591006AFWHITE DVDWoPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1VGEQO9Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-04-13ByDWo YYPhase 3A@ . . .N. A12-15 YearsNAHr8HsEZHr8Hr3,Hs$hHsEZPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW@YC4591001C4591001 1006 10061261DV100612611006AMWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZMN4C4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-22BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr3HrHr3..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061262DV100612621006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z4PJFLVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1006V102_VAX4 NO Non-Important2021-07-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsz\HrHr<Hs}.hHsz\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061267DV100612671006AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PG7JLHNasal swab not collected by site staff prior to vaccination. Laboratory VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs8HrHrڜHsSpHs8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061267DV100612671006AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1PG76QCProcedure not performed as part of vital signs. Procedures/Tests VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs8HrHrڜHsSpHs8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061267DV100612671006AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QZSYM3Other lab deviation Laboratory VACCINATION 1006V2_VAX2_L NO Non-Important2021-01-22B'DW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs8HrHrڜHsSpHs8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061269DV100612691006AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1PFF411Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006COVID_A1 NO Non-Important2021-02-10B:DW1 YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061269DV100612691006AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1VRXXYCVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006COVID_B1 NO Non-Important2021-04-27BDW} YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061269DV100612691006AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZMN4C7Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-06-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061269DV100612691006AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1YY0VDQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006V4_MONTH6_L NO Non-Important2021-06-29BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061272DV100612721006AFBLACK OR AFRICAN AMERICAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OXOQ5YParticipant met exclusion criterion #01 (participant having other medical or psychiatric condition) Inclusion/Exclusion VACCINATION 1006V1_DAY1_VAX1_L YES-POP2,YES-POP3Important 2020-12-16ADV YYPhase 3A@ . . .N. A12-15 YearsNAHrHsrHrHsr..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061274DV100612741006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1YBCOE9Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK8 NO Non-Important2021-05-25BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr?Hr1Hr?Hr1..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061274DV100612741006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YV6XRNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK10 NO Non-Important2021-06-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr?Hr1Hr?Hr1..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061274DV100612741006AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZD1VOBNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1006SSWAB_WEEK12 NO Non-Important2021-07-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr?Hr1Hr?Hr1..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061276DV100612761006AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YCQC4VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK8 NO Non-Important2021-05-11BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrKHs(HrKHrִHst8Hs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061277DV100612771006AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZE8TSOSerology sample not collected Laboratory FOLLOW-UP 1006V201_SURVEIL_CONSENT NO Non-Important2021-03-12BVDWO YYPhase 3A@ . . .N. A12-15 YearsNAHrpHs8 HrpHrpHssHs8 Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061278DV100612781006AMWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1R1DHHZNasal swab not collected for the visit where it is required Laboratory VACCINATION 1006COVID_A NO Non-Important2021-01-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrOHrHrO..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061280DV100612801006AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z2PN6TVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK14 NO Non-Important2021-07-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr6DHrHr6D..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061282DV100612821006AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XOV7IVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1006SSWAB_WEEK10 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr2tHrHr2t..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061284DV100612841006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YZ24R2Subject/LAR did not sign the ICD but gave verbal consent Informed Consent OPEN LABEL TREATMENT1006Consent NO Non-Important2021-06-15BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsLHrHrȅ0Hs|HsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061286DV100612861006AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z7HG8IVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK16 NO Non-Important2021-07-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrytHrHryt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1006 10061287DV100612871006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y71SN1Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1006V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr̄xHrHr̄x..Placebo Placebo .DWYC4591001C4591001 1006 10061287DV100612871006AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y71SMXReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1006V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-11BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr̄xHrHr̄x..Placebo Placebo .DWYC4591001C4591001 1006 10061299DV100612991006AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z7HG8MVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1006SSWAB_WEEK14 NO Non-Important2021-07-16BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrHrLHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071409DV100714091007AMASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA`1-1O6HZE1Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-01B)DV YYPhase 3A@ . . .N. A12-15 YearsNAHrad|HsnHrad|Hsn..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071409DV100714091007AMASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAp1-1OE7S8MVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2020-12-15B7DV YYPhase 3A@ . . .N. A12-15 YearsNAHrad|HsnHrad|Hsn..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071409DV100714091007AMASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1X12I7NVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V4_MONTH6_L NO Non-Important2021-05-10BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrad|HsnHrad|Hsn..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071409DV100714091007AMASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1ZBKAZ3Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1007Potential ReVax Initial Contact NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrad|HsnHrad|Hsn..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071409DV100714091007AMASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZZ4D8ZProcedure not recorded in source documentation as having been performed. Procedures/Tests REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrad|HsnHrad|Hsn..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071409DV100714091007AMASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZZ4D95Procedure not recorded in source documentation as having been performed. Procedures/Tests REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrad|HsnHrad|Hsn..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071409DV100714091007AMASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZZ4DCVProcedure not recorded in source documentation as having been performed. Procedures/Tests REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrad|HsnHrad|Hsn..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071409DV100714091007AMASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1ZZ4DCYProcedure not recorded in source documentation as having been performed. Procedures/Tests REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrad|HsnHrad|Hsn..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071414DV100714141007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTN7QVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK4 NO Non-Important2021-04-05BDWg YYPhase 3A@ . . .N. A12-15 YearsNAHraoHsaHHraoHr}+0Hsu|HsaHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071414DV100714141007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YHI2APOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHraoHsaHHraoHr}+0Hsu|HsaHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071414DV100714141007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YBCOECVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-06-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHraoHsaHHraoHr}+0Hsu|HsaHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071415DV100714151007AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z33ZY0Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsSCREENING 1007V2_VAX2_L YES-POP2,YES-POP3Important 2020-06-03DV5YNYPhase 3A@ . . .N. A12-15 YearsNAHrayHrHrayHr..Placebo Placebo .DWYC4591001C4591001 1007 10071415DV100714151007AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1O4BQN6Subject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1007V1_DAY1_VAX1_L NO Non-Important2020-11-06BDV YYPhase 3A@ . . .N. A12-15 YearsNAHrayHrHrayHr..Placebo Placebo .DWYC4591001C4591001 1007 10071415DV100714151007AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1OFD7VRProcedure not performed as part of vital signs. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-10B2DV YYPhase 3A@ . . .N. A12-15 YearsNAHrayHrHrayHr..Placebo Placebo .DWYC4591001C4591001 1007 10071415DV100714151007AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1OSO0FAVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-10B2DV YYPhase 3A@ . . .N. A12-15 YearsNAHrayHrHrayHr..Placebo Placebo .DWYC4591001C4591001 1007 10071415DV100714151007AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1OSO0FDVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-10B2DV YYPhase 3A@ . . .N. A12-15 YearsNAHrayHrHrayHr..Placebo Placebo .DWYC4591001C4591001 1007 10071415DV100714151007AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1OT9EZAVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-07BNDW YYPhase 3A@ . . .N. A12-15 YearsNAHrayHrHrayHr..Placebo Placebo .DWYC4591001C4591001 1007 10071415DV100714151007AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1X6ZYPNReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrayHrHrayHr..Placebo Placebo .DWYC4591001C4591001 1007 10071428DV100714281007AMASIAN DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z33ZY3Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsFOLLOW-UP 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHraHr}YHraHr}Y..Placebo Placebo .DWYC4591001C4591001 1007 10071428DV100714281007AMASIAN DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZBKAZ6Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1007Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHraHr}YHraHr}Y..Placebo Placebo .DWYC4591001C4591001 1007 10071428DV100714281007AMASIAN DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z340H3Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHraHr}YHraHr}Y..Placebo Placebo .DWYC4591001C4591001 1007 10071429DV100714291007AFWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y71SN4Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHraHr}\HraHr}\..Placebo Placebo .DWYC4591001C4591001 1007 10071429DV100714291007AFWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z340H6Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BDW YYPhase 3A@ . . .N. A12-15 YearsNAHraHr}\HraHr}\..Placebo Placebo .DWYC4591001C4591001 1007 10071471DV100714711007AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZQ9454Other Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-06-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr0HrHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071471DV100714711007AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZQ945KOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-06-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr0HrHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071472DV100714721007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTN7QYVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK2 NO Non-Important2021-04-08BDWj YYPhase 3A@ . . .N. A12-15 YearsNAHrHs,hHrHrjHsr_`Hs,hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071475DV100714751007AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ORZHPEOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-19B3DW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071475DV100714751007AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ORZHQYOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-19B3DW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071478DV100714781007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P947RROther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B@DW( YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrHHsv`LHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071478DV100714781007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P947RZOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B@DW( YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrHHsv`LHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071478DV100714781007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1P947RQRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B@DW( YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrHHsv`LHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071478DV100714781007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1P947RYRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B@DW( YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrHHsv`LHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071480DV100714801007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZQ94OLOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-11-30ADV YYPhase 3A@ . . .N. A12-15 YearsNAHr!|HsIHr!|HrHsrlHsIPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071480DV100714801007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XEB7A6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr!|HsIHr!|HrHsrlHsIPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071480DV100714801007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7ACOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr!|HsIHr!|HrHsrlHsIPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071480DV100714801007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7B2Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr!|HsIHr!|HrHsrlHsIPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071480DV100714801007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7B8Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr!|HsIHr!|HrHsrlHsIPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071481DV100714811007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZQP13IICD signed by subject/LAR had not received IRB/IEC approval Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071481DV100714811007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZQOYGKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071481DV100714811007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZQP122Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071481DV100714811007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZQP12IOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071482DV100714821007AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z9OU88Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-01ADV YYPhase 3A@ . . .Y. A12-15 YearsNAHr Hr Hr Hr ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071482DV100714821007AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1Z6VKZXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr Hr Hr Hr ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071483DV100714831007AFWHITE DVDWvPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WZ6CUNOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B9DW" YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsN$Hr`Hr۴Hs3ILHsN$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1007 10071483DV100714831007AFWHITE DVDWvPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WZ6XY0Other Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B9DW" YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsN$Hr`Hr۴Hs3ILHsN$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1007 10071483DV100714831007AFWHITE DVDWvPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WZ6Y09Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-03-30BxDWa YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsN$Hr`Hr۴Hs3ILHsN$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1007 10071484DV100714841007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UEGOPQOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B9DW" YYPhase 3A@ . . .N. A12-15 YearsNAHrpHs HrpHrhHsulHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071484DV100714841007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1UEGOQ6Other Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B9DW" YYPhase 3A@ . . .N. A12-15 YearsNAHrpHs HrpHrhHsulHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071484DV100714841007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7BEOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrpHs HrpHrhHsulHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071484DV100714841007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7BUOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrpHs HrpHrhHsulHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071484DV100714841007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7C0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrpHs HrpHrhHsulHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071484DV100714841007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEB7C6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrpHs HrpHrhHsulHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071492DV100714921007AFWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z340H9Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrs8Hr|Hrs8Hr|..Placebo Placebo .DWYC4591001C4591001 1007 10071492DV100714921007AFWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSXJDXReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrs8Hr|Hrs8Hr|..Placebo Placebo .DWYC4591001C4591001 1007 10071496DV100714961007AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEB5K9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-02ADV YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsQXHr`Hr0Hs{HsQXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071496DV100714961007AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XEBGQPOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsQXHr`Hr0Hs{HsQXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071496DV100714961007AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEBGQVOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsQXHr`Hr0Hs{HsQXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071496DV100714961007AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEBGXZOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsQXHr`Hr0Hs{HsQXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071496DV100714961007AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEBGY5Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsQXHr`Hr0Hs{HsQXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071497DV100714971007AMASIAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YBCOEGVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrĸHrHrĸHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071499DV100714991007AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X6ZYZRReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHrHrHr..Placebo Placebo .DWYC4591001C4591001 1007 10071499DV100714991007AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z35AVMReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHrHrHr..Placebo Placebo .DWYC4591001C4591001 1007 10071500DV100715001007AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZQUFJ0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-03ADV YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr8HrHr8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071505DV100715051007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1O9K7TRAssessment of acute reaction for protocol specified timeframe after study intervention administration not performed at the vaccination visits. Procedures/Tests VACCINATION 1007V1_DAY1_VAX1_L NO Non-Important2020-12-07ADV YYPhase 3A@ . . .N. A12-15 YearsNAHr`Hs3Hr`Hr,Hs_<Hs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071505DV100715051007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P947R2Other Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B9DW( YYPhase 3A@ . . .N. A12-15 YearsNAHr`Hs3Hr`Hr,Hs_<Hs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071505DV100715051007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P947RIOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-02-01B9DW( YYPhase 3A@ . . .N. A12-15 YearsNAHr`Hs3Hr`Hr,Hs_<Hs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071508DV100715081007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1P947S5Other Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-28B5DW$ YYPhase 3A@ . . .Y. A12-15 YearsNAHr)HrHr)Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071508DV100715081007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1P947SBOther Informed Consent Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-28B5DW$ YYPhase 3A@ . . .Y. A12-15 YearsNAHr)HrHr)Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071509DV100715091007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PNQNFWVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-17BIDW8 YYPhase 3A@ . . .N. A12-15 YearsNAHr6HsHr6HrOTHsv&HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071511DV100715111007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGLXT8Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHs7\HrTHrHss Hs7\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071511DV100715111007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGLXTEOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHs7\HrTHrHss Hs7\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071511DV100715111007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXTKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHs7\HrTHrHss Hs7\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071511DV100715111007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLXTQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHs7\HrTHrHss Hs7\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071515DV100715151007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1P947SUOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20B,DW YYPhase 3A@ . . .N. A12-15 YearsNAHrCHrHrCHr..Placebo Placebo .DWYC4591001C4591001 1007 10071515DV100715151007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1P947T0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20B,DW YYPhase 3A@ . . .N. A12-15 YearsNAHrCHrHrCHr..Placebo Placebo .DWYC4591001C4591001 1007 10071515DV100715151007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSXJE0Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrCHrHrCHr..Placebo Placebo .DWYC4591001C4591001 1007 10071515DV100715151007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YYPA1BReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrCHrHrCHr..Placebo Placebo .DWYC4591001C4591001 1007 10071518DV100715181007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-201T7WVRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-01-26B2DW" YYPhase 3A@ . . .Y. A12-15 YearsNAHrXHrxHrXHrx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071519DV100715191007AMWHITE DVDWwPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UEHIZ7Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-03-31BrDWb YYPhase 3A@ . . .N. A12-15 YearsNAHraHsP)HraHr Hs4LHHsP)Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWaYC4591001C4591001 1007 10071521DV100715211007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-201VBCZOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-06-17BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr|Hr:LHr|Hr:L..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071522DV100715221007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XM5NTEOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHs `HrXHr7|Hs~)0Hs `Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071522DV100715221007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XM5NTKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHs `HrXHr7|Hs~)0Hs `Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071522DV100715221007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM5NTQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHs `HrXHr7|Hs~)0Hs `Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071522DV100715221007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM5NTWOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHs `HrXHr7|Hs~)0Hs `Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071523DV100715231007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YGGO8HIncorrect serology sample volume collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-06-22BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrxHr HrxHr ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071524DV100715241007AMWHITE DVDWUPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1P947TAOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-02-01B8DW( YYPhase 3A@ . . .N. A12-15 YearsNAHrdHs#rHrdHr HsLHs#rPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW1YC4591001C4591001 1007 10071524DV100715241007AMWHITE DVDWUPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P947TGOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-02-01B8DW( YYPhase 3A@ . . .N. A12-15 YearsNAHrdHs#rHrdHr HsLHs#rPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW1YC4591001C4591001 1007 10071524DV100715241007AMWHITE DVDWUPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1PDX794Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-03B:DW* YYPhase 3A@ . . .N. A12-15 YearsNAHrdHs#rHrdHr HsLHs#rPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW1YC4591001C4591001 1007 10071524DV100715241007AMWHITE DVDWUPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YLJ7SARevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-02-25BPDW@ YYPhase 3A@ . . .N. A12-15 YearsNAHrdHs#rHrdHr HsLHs#rPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW1YC4591001C4591001 1007 10071525DV100715251007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1PDX799Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-03B:DW* YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr @HrHr @..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071528DV100715281007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z35AVSReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHryHrHry..Placebo Placebo .DWYC4591001C4591001 1007 10071528DV100715281007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z35B5LReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHryHrHry..Placebo Placebo .DWYC4591001C4591001 1007 10071529DV100715291007AFMULTIPLE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OAL5G0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-09ADV YYPhase 3A@ . . .Y. A12-15 YearsNAHr0HrLHHr0HrLH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071529DV100715291007AFMULTIPLE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1YBCOEJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr0HrLHHr0HrLH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071530DV100715301007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XK3Y7FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-06-01BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrPHrHrP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1PNR0W3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-17BGDW8 YYPhase 3A@ . . .N. A12-15 YearsNAHrhHsHrhHrSHs|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XM737SOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrhHsHrhHrSHs|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XM7388Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrhHsHrhHrSHs|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM738EOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrhHsHrhHrSHs|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM73FIOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrhHsHrhHrSHs|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XK3Y7IVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007COVID_B1 NO Non-Important2021-06-01BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrhHsHrhHrSHs|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YV6XRQVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-06-22BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrhHsHrhHrSHs|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071531DV100715311007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCDLPJVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1007V103_MONTH1 NO Non-Important2021-07-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrhHsHrhHrSHs|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071533DV100715331007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBBEUOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrxHsHrxHrbPHs~$HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071533DV100715331007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XMBBFKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrxHsHrxHrbPHs~$HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071533DV100715331007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBGUOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrxHsHrxHrbPHs~$HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071533DV100715331007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBH0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrxHsHrxHrbPHs~$HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071536DV100715361007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YBCOEMVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHHrHrH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071536DV100715361007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1Z6G6WBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-06-17BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHHrHrH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071537DV100715371007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OTC5LJVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2020-12-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrҰHr\HrҰHr\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071537DV100715371007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OT8120Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-29B4DW% YYPhase 3A@ . . .Y. A12-15 YearsNAHrҰHr\HrҰHr\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071539DV100715391007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Y5U9OORevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-02BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHs<HrTHrHsHs<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071540DV100715401007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WYEJXDVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-05-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs9(HrHrHsHs9(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071540DV100715401007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YG8TD7Serology sample not collected Laboratory OPEN LABEL TREATMENT1007COVID_B1 NO Non-Important2021-06-02BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs9(HrHrHsHs9(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071540DV100715401007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YGE03FVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007COVID_B1 NO Non-Important2021-06-02BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs9(HrHrHsHs9(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071541DV100715411007AMWHITE DVDWEPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YHI2ITRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-02-09B?DW0 YYPhase 3A@ . . .N. A12-15 YearsNAHrHsMHrHrHrHsMPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW/YC4591001C4591001 1007 10071542DV100715421007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YBCOEZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071543DV100715431007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X6ZYZUReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HrHr<Hr..Placebo Placebo .DWYC4591001C4591001 1007 10071543DV100715431007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Y24OS3Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HrHr<Hr..Placebo Placebo .DWYC4591001C4591001 1007 10071543DV100715431007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YG8TDASerology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-06-23BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HrHr<Hr..Placebo Placebo .DWYC4591001C4591001 1007 10071547DV100715471007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XKP12AOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs HrHrX<HsvbHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071547DV100715471007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XKP12QOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs HrHrX<HsvbHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071547DV100715471007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XKP136Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs HrHrX<HsvbHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071547DV100715471007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XKP13COther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs HrHrX<HsvbHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071547DV100715471007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XKP13IOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs HrHrX<HsvbHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071551DV100715511007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1PP8P75Nasal swab not collected for the visit where it is required Laboratory VACCINATION 1007COVID_A NO Non-Important2020-12-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr1PHscHr1PHr/Hs{HscPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071551DV100715511007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1R2MXMQVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-03-02BSDWE YYPhase 3A@ . . .N. A12-15 YearsNAHr1PHscHr1PHr/Hs{HscPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071551DV100715511007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XKP15MOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr1PHscHr1PHr/Hs{HscPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071551DV100715511007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XKP15SOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr1PHscHr1PHr/Hs{HscPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071551DV100715511007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XKP168Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr1PHscHr1PHr/Hs{HscPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071551DV100715511007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XKP16EOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr1PHscHr1PHr/Hs{HscPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071551DV100715511007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XKP16KOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr1PHscHr1PHr/Hs{HscPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071551DV100715511007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YG8U0FVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007COVID_B1 NO Non-Important2021-06-22BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr1PHscHr1PHr/Hs{HscPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071552DV100715521007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XMBBHQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrFHsHrFHr/Hs~VlHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071552DV100715521007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XMBBJAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrFHsHrFHr/Hs~VlHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071552DV100715521007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBJGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrFHsHrFHr/Hs~VlHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071552DV100715521007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBKQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrFHsHrFHr/Hs~VlHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071554DV100715541007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XD2IB4Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-22BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrJdHr<HrJdHr<..Placebo Placebo .DWYC4591001C4591001 1007 10071554DV100715541007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z35B5OReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrJdHr<HrJdHr<..Placebo Placebo .DWYC4591001C4591001 1007 10071555DV100715551007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XGK0G5Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-05-27BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrEHrG0HrEHrG0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071555DV100715551007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1Z4VSKLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrEHrG0HrEHrG0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071557DV100715571007AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1YBEU83Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-10BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr*HrHr*Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071557DV100715571007AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBB9L3Serology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-22BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr*HrHr*Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071557DV100715571007AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZB3SZXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-22BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr*HrHr*Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PFSWJZOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21B'DW YYPhase 3A@ . . .N. A12-15 YearsNAHrI`Hs-HrI`Hr.HsHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PFSWK5Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21B'DW YYPhase 3A@ . . .N. A12-15 YearsNAHrI`Hs-HrI`Hr.HsHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBNSOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrI`Hs-HrI`Hr.HsHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBNYOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrI`Hs-HrI`Hr.HsHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XMBBO4Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrI`Hs-HrI`Hr.HsHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071559DV100715591007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XMBBOAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrI`Hs-HrI`Hr.HsHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1UEHUXJRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-03-14B[DWQ YYPhase 3A@ . . .N. A12-15 YearsNAHrlLHs+HrlLHr-Hsr]Hs+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1UEHUXPRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent FOLLOW-UP 1007Consent NO Non-Important2021-03-16B]DWS YYPhase 3A@ . . .N. A12-15 YearsNAHrlLHs+HrlLHr-Hsr]Hs+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGL7AYOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlLHs+HrlLHr-Hsr]Hs+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGL7B4Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlLHs+HrlLHr-Hsr]Hs+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGL7BKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlLHs+HrlLHr-Hsr]Hs+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071560DV100715601007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGL7BQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlLHs+HrlLHr-Hsr]Hs+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071562DV100715621007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGL7C6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrB<HsrIHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071562DV100715621007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGL7CCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrB<HsrIHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071562DV100715621007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGL7DCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrB<HsrIHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071562DV100715621007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGL7DSOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrB<HsrIHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071563DV100715631007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGL7DYOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlHs HrlHr@HsrJHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071563DV100715631007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGL7EEOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlHs HrlHr@HsrJHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071563DV100715631007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGL7EKOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlHs HrlHr@HsrJHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071563DV100715631007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGL7EQOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlHs HrlHr@HsrJHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071564DV100715641007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONNA3KOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071564DV100715641007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONNA3QOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071564DV100715641007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1OT812GVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071564DV100715641007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1TE4I2PVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071564DV100715641007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1PFF365Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-08B9DW/ YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071565DV100715651007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONN9JXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr@HrHr@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071565DV100715651007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONN9K3Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr@HrHr@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071565DV100715651007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1OT812JVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr@HrHr@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071566DV100715661007AMWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1P2RFXFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-01B2DW( YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr;4HrHr;4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071566DV100715661007AMWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1Z3S3BPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr;4HrHr;4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071566DV100715661007AMWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YYQVO9Serology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr;4HrHr;4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071566DV100715661007AMWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZE8TVSSerology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr;4HrHr;4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071567DV100715671007AMWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONN9K9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr%XHrHr%X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071567DV100715671007AMWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONO00XOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr%XHrHr%X..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071568DV100715681007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSZQCJRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsHr`HrĆ`HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071568DV100715681007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSZQDTRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsHr`HrĆ`HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071569DV100715691007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO04POther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrfHsXHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071569DV100715691007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO04VOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrfHsXHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071570DV100715701007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO051Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrPHs0HrPHreHsHs0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071570DV100715701007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO057Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrPHs0HrPHreHsHs0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071571DV100715711007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONO05NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr݀HrHr݀..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071571DV100715711007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONO05TOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr݀HrHr݀..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071571DV100715711007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1Z3S3BTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK6 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr݀HrHr݀..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071572DV100715721007AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONO061Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr<Hrą4Hr<Hrą4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071572DV100715721007AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONO08ZOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr<Hrą4Hr<Hrą4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071573DV100715731007AMWHITE DVDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSXJK7Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHr'HrXHr'..Placebo Placebo .DWYC4591001C4591001 1007 10071574DV100715741007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1UEHV0TRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-03-13BXDWP YYPhase 3A@ . . .Y. A12-15 YearsNAHr HrŲHr HrŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071574DV100715741007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1VITA5CParticipant entered into asymptomatic swabbing part of study after they were unblinded Other REPEAT SCREENING 1 1007V201_SURVEIL_CONSENT NO Non-Important2021-03-17B\DWT YYPhase 3A@ . . .Y. A12-15 YearsNAHr HrŲHr HrŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071574DV100715741007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YBEU87Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-03BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr HrŲHr HrŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071574DV100715741007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1Z2PN6XVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-07-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr HrŲHr HrŲ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071575DV100715751007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONO0H7Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071575DV100715751007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONO0HDOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1007 10071576DV100715761007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSZQBDRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrӨHslHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW}YC4591001C4591001 1007 10071576DV100715761007AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSZQCDRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrӨHslHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW}YC4591001C4591001 1007 10071577DV100715771007AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO0HJOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsjO<Hr<HrHsMPHsjO<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWpYC4591001C4591001 1007 10071577DV100715771007AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO0HPOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsjO<Hr<HrHsMPHsjO<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWpYC4591001C4591001 1007 10071577DV100715771007AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WZ7GVDOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-04-19B}DWu YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsjO<Hr<HrHsMPHsjO<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWpYC4591001C4591001 1007 10071578DV100715781007AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO0IFOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr:HsWpHr:HrLHs{HsWpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071578DV100715781007AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO0ILOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr:HsWpHr:HrLHs{HsWpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071578DV100715781007AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XKVLC5Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr:HsWpHr:HrLHs{HsWpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071578DV100715781007AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XKVLCBOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr:HsWpHr:HrLHs{HsWpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071578DV100715781007AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XKVLD1Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr:HsWpHr:HrLHs{HsWpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071578DV100715781007AMMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XKVLDHOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr:HsWpHr:HrLHs{HsWpPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071579DV100715791007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONO0IROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrHr=Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071579DV100715791007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONO0JROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrHr=Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071579DV100715791007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1Z4VSKOVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-16BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrHr=Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071580DV100715801007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONO0JXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr>HrHr>Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071580DV100715801007AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONO0KXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr>HrHr>Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071581DV100715811007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO0LDOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrulHs3HrulHr$Hs{dHs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071581DV100715811007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONO0LJOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrulHs3HrulHr$Hs{dHs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071581DV100715811007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XKVLDNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrulHs3HrulHr$Hs{dHs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071581DV100715811007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XKVLENOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrulHs3HrulHr$Hs{dHs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071581DV100715811007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XKVLETOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrulHs3HrulHr$Hs{dHs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071581DV100715811007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XKVLEZOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrulHs3HrulHr$Hs{dHs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071582DV100715821007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONO0M9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrwHr#HrwHr#..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071582DV100715821007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONO0MFOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrwHr#HrwHr#..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071582DV100715821007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XQ1WEJNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007COVID_A NO Non-Important2021-06-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrwHr#HrwHr#..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071582DV100715821007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1YV6XRTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrwHr#HrwHr#..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071582DV100715821007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1Z3A98TSerology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrwHr#HrwHr#..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071583DV100715831007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONO0MVOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsxHrHr&Hss(HsxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071583DV100715831007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONOEJLOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsxHrHr&Hss(HsxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071583DV100715831007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXUZOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsxHrHr&Hss(HsxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071583DV100715831007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLZ4ROther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsxHrHr&Hss(HsxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071583DV100715831007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGLZ4XOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsxHrHr&Hss(HsxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071583DV100715831007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGLZ53Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsxHrHr&Hss(HsxPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071584DV100715841007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONOEJROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr}Hr*PHr}Hr*P..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071584DV100715841007AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONOEKROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr}Hr*PHr}Hr*P..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071585DV100715851007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONOEKXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr~THslHr~THr'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071585DV100715851007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONOEUTOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr~THslHr~THr'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071585DV100715851007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXP0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr~THslHr~THr'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071585DV100715851007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLXP6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr~THslHr~THr'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071585DV100715851007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGLXPMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr~THslHr~THr'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071585DV100715851007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGLXQCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr~THslHr~THr'Hsr@HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071586DV100715861007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ONOEYLOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr$HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071586DV100715861007AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ONOEYROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr$HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071587DV100715871007AFASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ONOF8EOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr+@HrHr+@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071587DV100715871007AFASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ONOF8KOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr+@HrHr+@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071588DV100715881007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS17WXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr@HrHr@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071588DV100715881007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS17X3Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr@HrHr@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071588DV100715881007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XTPZXZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr@HrHr@..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071589DV100715891007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORAYSGOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr HsðHr Hr֢HssHsðPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071589DV100715891007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ORAYUUOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr HsðHr Hr֢HssHsðPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071589DV100715891007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLZ59Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr HsðHr Hr֢HssHsðPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071589DV100715891007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLZ5FOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr HsðHr Hr֢HssHsðPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071589DV100715891007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGLZ5LOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr HsðHr Hr֢HssHsðPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071589DV100715891007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGLZ5ROther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr HsðHr Hr֢HssHsðPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071591DV100715911007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORAYW0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsHr`Hr֛HHsb HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071591DV100715911007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZA1F4URevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-02BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsHr`Hr֛HHsb HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071592DV100715921007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ORBV52Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr֝HrHr֝..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071592DV100715921007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ORBV58Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr֝HrHr֝..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071592DV100715921007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1QYQAN1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B;DW? YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr֝HrHr֝..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071592DV100715921007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1XTPZY3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr֝HrHr֝..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071593DV100715931007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QZCJI9Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsVACCINATION 1007V1_DAY1_VAX1_L YES-POP2,YES-POP3Important 2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr͜Hr͜Hr͜Hr͜..Placebo .DW3YC4591001C4591001 1007 10071593DV100715931007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1T5A5N5Blind broken outside of IRT when not permitted per protocol Procedures/Tests REPEAT SCREENING 1 1007V1_DAY1_VAX1_L NO Non-Important2021-02-12B/DW3 YYPhase 3A@ . . .N. A12-15 YearsNAHr͜Hr͜Hr͜Hr͜..Placebo .DW3YC4591001C4591001 1007 10071594DV100715941007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OROZM3Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-28ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrdHrLHrd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071594DV100715941007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OROZMHOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-28ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrdHrLHrd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071594DV100715941007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YV6XRWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrdHrLHrd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071595DV100715951007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORBV5FOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs|HrHrֱPHss$Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071595DV100715951007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ORBVGPOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs|HrHrֱPHss$Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071595DV100715951007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGOXRROther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs|HrHrֱPHss$Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071595DV100715951007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGOXRXOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs|HrHrֱPHss$Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071595DV100715951007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGOXS3Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs|HrHrֱPHss$Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071595DV100715951007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGOXS9Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs|HrHrֱPHss$Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071596DV100715961007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OVTH5SOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs5tHrHrDpHs{Hs5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071596DV100715961007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OVTH5YOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs5tHrHrDpHs{Hs5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071596DV100715961007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM5FNNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs5tHrHrDpHs{Hs5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071596DV100715961007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM5FNTOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs5tHrHrDpHs{Hs5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071596DV100715961007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XM5FNZOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs5tHrHrDpHs{Hs5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071596DV100715961007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XM737HOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-24BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs5tHrHrDpHs{Hs5tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071597DV100715971007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS17Z9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071597DV100715971007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS17ZFOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071597DV100715971007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YBEU8AVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK14 NO Non-Important2021-06-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071599DV100715991007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ORBVH1Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr¨HrHr¨..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071599DV100715991007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ORBVHPOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr¨HrHr¨..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071599DV100715991007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1XTPZY6Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr¨HrHr¨..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071599DV100715991007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZIM294Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007SSWAB_WEEK16 NO Non-Important2021-07-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr¨HrHr¨..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071599DV100715991007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1ZHUT2GVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK18 NO Non-Important2021-07-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr¨HrHr¨..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071600DV100716001007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORBVHWOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHslHs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071600DV100716001007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ORC2NKOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHslHs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071600DV100716001007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YJ4OMAOther Informed Consent Informed Consent REPEAT SCREENING 1 1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHslHs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071600DV100716001007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YD7IBXSerology sample not collected Laboratory OPEN LABEL TREATMENT1007V101_VAX3 NO Non-Important2021-06-01BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHslHs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071600DV100716001007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1Z6VL01Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-07-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHslHs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071601DV100716011007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS17ZMOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr(HrHr(Hr..Placebo Placebo .DWYC4591001C4591001 1007 10071601DV100716011007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OS17ZSOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr(HrHr(Hr..Placebo Placebo .DWYC4591001C4591001 1007 10071601DV100716011007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Z4WZO6Serology sample not collected Laboratory FOLLOW-UP 1007V201_SURVEIL_CONSENT NO Non-Important2021-03-16BODWS YYPhase 3A@ . . .N. A12-15 YearsNAHr(HrHr(Hr..Placebo Placebo .DWYC4591001C4591001 1007 10071601DV100716011007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1SMY9AMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-16BODWS YYPhase 3A@ . . .N. A12-15 YearsNAHr(HrHr(Hr..Placebo Placebo .DWYC4591001C4591001 1007 10071601DV100716011007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YBYR3OReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr(HrHr(Hr..Placebo Placebo .DWYC4591001C4591001 1007 10071601DV100716011007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZCDLPNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-29BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr(HrHr(Hr..Placebo Placebo .DWYC4591001C4591001 1007 10071602DV100716021007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS189QOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071602DV100716021007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS189XOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071602DV100716021007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YBEU8NVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071603DV100716031007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS1U2AOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr HrHr ..Placebo Placebo .DWYC4591001C4591001 1007 10071603DV100716031007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OS1U2GOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr HrHr ..Placebo Placebo .DWYC4591001C4591001 1007 10071603DV100716031007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSXJKAReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr HrHr ..Placebo Placebo .DWYC4591001C4591001 1007 10071604DV100716041007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OS1U2NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr,HrHr,..Placebo Placebo .DWYC4591001C4591001 1007 10071604DV100716041007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1OS1U3DOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr,HrHr,..Placebo Placebo .DWYC4591001C4591001 1007 10071604DV100716041007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z4VTMYReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr,HrHr,..Placebo Placebo .DWYC4591001C4591001 1007 10071604DV100716041007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z4VTN1Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr,HrHr,..Placebo Placebo .DWYC4591001C4591001 1007 10071605DV100716051007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ORC2O1Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr\Hr֥\Hr\Hr֥\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071605DV100716051007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ORC2O7Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr\Hr֥\Hr\Hr֥\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071605DV100716051007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YBEU8QVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-10BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr\Hr֥\Hr\Hr֥\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071606DV100716061007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS1U4OOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrDHrHrDHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071606DV100716061007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS1U4UOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrDHrHrDHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071606DV100716061007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1R24MVTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-04BBDWG YYPhase 3A@ . . .Y. A12-15 YearsNAHrDHrHrDHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071606DV100716061007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1YV6XRZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK10 NO Non-Important2021-06-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrDHrHrDHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071606DV100716061007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1Z8JZKXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK14 NO Non-Important2021-07-18BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrDHrHrDHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071607DV100716071007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS1U7JOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr44HsHr44Hr HssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071607DV100716071007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS1U7POther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr44HsHr44Hr HssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071607DV100716071007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1QYQPR7Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B:DW? YYPhase 3A@ . . .N. A12-15 YearsNAHr44HsHr44Hr HssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071607DV100716071007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7CCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr44HsHr44Hr HssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071607DV100716071007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7CIOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr44HsHr44Hr HssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071607DV100716071007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7DIOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr44HsHr44Hr HssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071607DV100716071007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEB7E3Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr44HsHr44Hr HssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071607DV100716071007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YG8TEQVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007COVID_A1 NO Non-Important2021-06-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr44HsHr44Hr HssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071608DV100716081007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS1U7WOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr2HsHr2HrHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071608DV100716081007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS29Q4Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr2HsHr2HrHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071608DV100716081007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QYQPRBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B:DW? YYPhase 3A@ . . .N. A12-15 YearsNAHr2HsHr2HrHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071608DV100716081007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1X75PELLab performed out of window Laboratory REPEAT SCREENING 1 1007COVID_A NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr2HsHr2HrHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071608DV100716081007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7E9Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr2HsHr2HrHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071608DV100716081007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7EFOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr2HsHr2HrHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071608DV100716081007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7FAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr2HsHr2HrHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071608DV100716081007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEB7FGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr2HsHr2HrHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071609DV100716091007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS29UROther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr9\HrHHr9\HrH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071609DV100716091007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS29UXOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr9\HrHHr9\HrH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071609DV100716091007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1WTN7R1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK10 NO Non-Important2021-04-28ByDW~ YYPhase 3A@ . . .Y. A12-15 YearsNAHr9\HrHHr9\HrH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071609DV100716091007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1WTN7R4Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-04-28ByDW~ YYPhase 3A@ . . .Y. A12-15 YearsNAHr9\HrHHr9\HrH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071609DV100716091007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1XTQ01LVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr9\HrHHr9\HrH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071610DV100716101007AFAMERICAN INDIAN OR ALASKA NATIVE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OVTT3BOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrٜHr=Hrٜ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW}YC4591001C4591001 1007 10071610DV100716101007AFAMERICAN INDIAN OR ALASKA NATIVE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OVTT3HOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrٜHr=Hrٜ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW}YC4591001C4591001 1007 10071612DV100716121007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS2K9AOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr;HrPHr;HrP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071612DV100716121007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS2K9GOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr;HrPHr;HrP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071612DV100716121007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1QZP5B3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-25B;DW@ YYPhase 3A@ . . .Y. A12-15 YearsNAHr;HrPHr;HrP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071612DV100716121007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1U7XBCALab performed out of window Laboratory FOLLOW-UP 1007SSWAB_WEEK4 NO Non-Important2021-03-29B[DW` YYPhase 3A@ . . .Y. A12-15 YearsNAHr;HrPHr;HrP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071612DV100716121007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA`1-1YBEU8TVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr;HrPHr;HrP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071612DV100716121007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1ZIM297Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007SSWAB_WEEK16 NO Non-Important2021-07-10BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr;HrPHr;HrP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071612DV100716121007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAp1-1ZHUT51Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK18 NO Non-Important2021-07-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr;HrPHr;HrP..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071613DV100716131007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS2KA7Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrM HslHrM Hr(Hs|4HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071613DV100716131007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS2KADOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrM HslHrM Hr(Hs|4HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071613DV100716131007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YCQC4YVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-03-31B]DWb YYPhase 3A@ . . .N. A12-15 YearsNAHrM HslHrM Hr(Hs|4HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071613DV100716131007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEB7FMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrM HslHrM Hr(Hs|4HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071613DV100716131007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEB7XBOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrM HslHrM Hr(Hs|4HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071613DV100716131007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEB7XHOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrM HslHrM Hr(Hs|4HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071613DV100716131007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEB7XNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrM HslHrM Hr(Hs|4HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071614DV100716141007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ORC1XTOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrS`Hs|HrS`HrHsvq,Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071614DV100716141007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ORC1XZOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrS`Hs|HrS`HrHsvq,Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071614DV100716141007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEBGKXOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrS`Hs|HrS`HrHsvq,Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071614DV100716141007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEBGLNOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrS`Hs|HrS`HrHsvq,Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071614DV100716141007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XEBGM3Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrS`Hs|HrS`HrHsvq,Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071614DV100716141007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XEBGMJOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrS`Hs|HrS`HrHsvq,Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071614DV100716141007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YV6XS2Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-06-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrS`Hs|HrS`HrHsvq,Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071615DV100716151007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS2KAKOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrxHrLHrx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071615DV100716151007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS2KEWOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrxHrLHrx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071615DV100716151007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XNE0EFVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-06-02BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrxHrLHrx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071615DV100716151007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1YBEU8WVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrxHrLHrx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071615DV100716151007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1Z499HLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK16 NO Non-Important2021-07-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHrxHrLHrx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071616DV100716161007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS2KFDOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrQDHr4HrQDHr4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071616DV100716161007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS2KFJOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrQDHr4HrQDHr4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071616DV100716161007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YBEUAXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-03BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrQDHr4HrQDHr4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071616DV100716161007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1ZCDLPQVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrQDHr4HrQDHr4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071617DV100716171007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OVTT4IOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr[XHsi^Hr[XHrLhHsMGHsi^Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWjYC4591001C4591001 1007 10071617DV100716171007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OVTT58Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr[XHsi^Hr[XHrLhHsMGHsi^Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWjYC4591001C4591001 1007 10071618DV100716181007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ORC1Y6Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr[Hr֜Hr[Hr֜..Placebo Placebo .DWYC4591001C4591001 1007 10071618DV100716181007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ORC1YCOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr[Hr֜Hr[Hr֜..Placebo Placebo .DWYC4591001C4591001 1007 10071618DV100716181007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1QYQPREVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-24B:DW? YYPhase 3A@ . . .N. A12-15 YearsNAHr[Hr֜Hr[Hr֜..Placebo Placebo .DWYC4591001C4591001 1007 10071618DV100716181007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSXJKGReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr[Hr֜Hr[Hr֜..Placebo Placebo .DWYC4591001C4591001 1007 10071618DV100716181007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XQC5GNNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007COVID_A NO Non-Important2021-06-01BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr[Hr֜Hr[Hr֜..Placebo Placebo .DWYC4591001C4591001 1007 10071618DV100716181007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XSXJKDReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-03BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr[Hr֜Hr[Hr֜..Placebo Placebo .DWYC4591001C4591001 1007 10071619DV100716191007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS2KG0Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrCHrHrCHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071619DV100716191007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS2KG6Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrCHrHrCHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071619DV100716191007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XTQ01OVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrCHrHrCHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071620DV100716201007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1QO6A4ISAE report delayed or not reported to Sponsor Safety Reporting VACCINATION 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-01B"DW( YYPhase 3A@ . . .Y. A12-15 YearsNAHrM8HrRHrM8HrR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071620DV100716201007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1R1DOTBNasal swab not collected for the visit where it is required Laboratory VACCINATION 1007COVID_A NO Non-Important2021-02-05B&DW, YYPhase 3A@ . . .Y. A12-15 YearsNAHrM8HrRHrM8HrR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071620DV100716201007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1ZHW9RZVisit not done Visit Schedule VACCINATION 1007COVID_A1 NO Non-Important2021-02-05B&DW, YYPhase 3A@ . . .Y. A12-15 YearsNAHrM8HrRHrM8HrR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071620DV100716201007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1V8MALINasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1007COVID_B NO Non-Important2021-03-16BMDWS YYPhase 3A@ . . .Y. A12-15 YearsNAHrM8HrRHrM8HrR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071620DV100716201007AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1TB4AGZSAE report delayed or not reported to Sponsor Safety Reporting FOLLOW-UP 1007Unplanned NO Non-Important2021-03-16BMDWS YYPhase 3A@ . . .Y. A12-15 YearsNAHrM8HrRHrM8HrR..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071621DV100716211007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OVTTR7Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrQHrRHrQHrR..Placebo Placebo .DWYC4591001C4591001 1007 10071621DV100716211007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OVTTRDOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrQHrRHrQHrR..Placebo Placebo .DWYC4591001C4591001 1007 10071622DV100716221007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OVU6X8Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrPDHrPDHrPDHrPD..BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1007 10071622DV100716221007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OVU6X6Subject/LAR signed a superseded/outdated version of the ICD Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrPDHrPDHrPDHrPD..BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1007 10071622DV100716221007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1PPEUWTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-18B3DW9 YYPhase 3A@ . . .N. A12-15 YearsNAHrPDHrPDHrPDHrPD..BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW6YC4591001C4591001 1007 10071623DV100716231007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OROZMNOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHslHrTHr٢HsLHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071623DV100716231007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OROZMUOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHslHrTHr٢HsLHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071623DV100716231007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OVVC18Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHslHrTHr٢HsLHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071623DV100716231007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1OVVC3MOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHslHrTHr٢HsLHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071623DV100716231007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZE8TVVSerology sample not collected Laboratory OPEN LABEL TREATMENT1007V101_VAX3 NO Non-Important2021-06-01BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrTHslHrTHr٢HsLHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071624DV100716241007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1OVVC8OVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAHre Hs$4Hre HrdHsuXHs$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071624DV100716241007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XEBGN9Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHre Hs$4Hre HrdHsuXHs$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071624DV100716241007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XEBGNPOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHre Hs$4Hre HrdHsuXHs$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071624DV100716241007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XEBGNVOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHre Hs$4Hre HrdHsuXHs$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071624DV100716241007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XEBGQJOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHre Hs$4Hre HrdHsuXHs$4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OZPL4WOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAHrg<Hs"Hrg<HrtHsuHs"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OZPL52Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAHrg<Hs"Hrg<HrtHsuHs"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1OZPL53Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAHrg<Hs"Hrg<HrtHsuHs"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGOY0BOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrg<Hs"Hrg<HrtHsuHs"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGOY61Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrg<Hs"Hrg<HrtHsuHs"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGOY67Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrg<Hs"Hrg<HrtHsuHs"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071625DV100716251007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGOY6DOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrg<Hs"Hrg<HrtHsuHs"Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071626DV100716261007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OS2KGPOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071626DV100716261007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OS2KGVOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071626DV100716261007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XTQ01RVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-03BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071627DV100716271007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OROZN8Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071627DV100716271007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OROZNMOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2020-12-30ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071627DV100716271007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XT1VKJVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071627DV100716271007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1XTQ01UVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071628DV100716281007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OZPL49Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr0HrHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071628DV100716281007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OZPL4NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr0HrHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071628DV100716281007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1Z3S3BWVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-22BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr0HrHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071628DV100716281007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZIM22UNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007SSWAB_WEEK14 NO Non-Important2021-07-10BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr0HrHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071628DV100716281007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1ZIM291Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1007SSWAB_WEEK16 NO Non-Important2021-07-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr0HrHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071628DV100716281007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA`1-1ZCT7KBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-08-02BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr0HrHr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071629DV100716291007AFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS2KJ9Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsτHrHr@Hs<HsτPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071629DV100716291007AFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS2KJFOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsτHrHr@Hs<HsτPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071630DV100716301007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS2KJWOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHs>Hs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071630DV100716301007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OS2KKCOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHs>Hs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071630DV100716301007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM73FOOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-01BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHs>Hs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071630DV100716301007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM73G4Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-01BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHs>Hs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071630DV100716301007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XM73GAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-01BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHs>Hs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071630DV100716301007AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XM73GGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-06-01BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHs>Hs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071631DV100716311007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OZPL3HOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrٝpHrHrٝp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071631DV100716311007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OZPL3NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrٝpHrHrٝp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071632DV100716321007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OZPL2KOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr Hs9Hr Hr]HssPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071632DV100716321007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OZPL2QOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr Hs9Hr Hr]HssPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071632DV100716321007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGOXSFOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr Hs9Hr Hr]HssPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071632DV100716321007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGOXZJOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr Hs9Hr Hr]HssPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071632DV100716321007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGOXZPOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr Hs9Hr Hr]HssPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071632DV100716321007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XGOY05Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr Hs9Hr Hr]HssPHs9Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071633DV100716331007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OZPL27Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr٠|HrHr٠|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071633DV100716331007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OZPL2DOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr٠|HrHr٠|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071633DV100716331007AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XTQ01XVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr٠|HrHr٠|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071634DV100716341007AMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OZPL1UOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrޜlHrHrޜl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071634DV100716341007AMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OZPL20Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrޜlHrHrޜl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071635DV100716351007AMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OZPL1HOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAHrHrPHrHrP..Placebo Placebo .DWYC4591001C4591001 1007 10071635DV100716351007AMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OZPL1NOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAHrHrPHrHrP..Placebo Placebo .DWYC4591001C4591001 1007 10071635DV100716351007AMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XD2IB7Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHrPHrHrP..Placebo Placebo .DWYC4591001C4591001 1007 10071636DV100716361007AFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XTQ020Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-03BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrގ HrHrގ ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071638DV100716381007AFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OZPDF2Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAHr<HrއHr<Hrއ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071638DV100716381007AFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OZPDFIOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAHr<HrއHr<Hrއ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071638DV100716381007AFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1Z4VZVTVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr<HrއHr<Hrއ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071638DV100716381007AFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1Z499HPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-07-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr<HrއHr<Hrއ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071639DV100716391007AMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OZP63AOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAHrHrށHrHrށ..Placebo Placebo .DWYC4591001C4591001 1007 10071639DV100716391007AMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OZP63GOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAHrHrށHrHrށ..Placebo Placebo .DWYC4591001C4591001 1007 10071639DV100716391007AMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZIM22PNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-04-19BjDWu YYPhase 3A@ . . .N. A12-15 YearsNAHrHrށHrHrށ..Placebo Placebo .DWYC4591001C4591001 1007 10071639DV100716391007AMWHITE DW DW!Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZHUT54Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK8 NO Non-Important2021-04-28BsDW~ YYPhase 3A@ . . .N. A12-15 YearsNAHrHrށHrHrށ..Placebo Placebo .DWYC4591001C4591001 1007 10071640DV100716401007AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R0CRESVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-02B:DWE YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr@HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OXAG96Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .Y. A12-15 YearsNAHr(Hr-Hr(Hr-..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OXAG9COther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .Y. A12-15 YearsNAHr(Hr-Hr(Hr-..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XD2IEMVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_A1 NO Non-Important2021-05-24BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr(Hr-Hr(Hr-..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1XTQ023Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr(Hr-Hr(Hr-..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1ZB3T01Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK18 NO Non-Important2021-07-26BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr(Hr-Hr(Hr-..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071641DV100716411007AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA`1-1ZFDTHSVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007COVID_B1 NO Non-Important2021-08-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr(Hr-Hr(Hr-..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071642DV100716421007AMWHITE DW DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OWKIN5Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr%,Hs8Hr%,Hs8..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071642DV100716421007AMWHITE DW DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OWKINBOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr%,Hs8Hr%,Hs8..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071642DV100716421007AMWHITE DW DWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1QSQ8I6Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-22B2DW= YYPhase 3A@ . . .N. A12-15 YearsNAHr%,Hs8Hr%,Hs8..BNT162b2 (30 (*ESC*){unicode 03BC}g) BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071643DV100716431007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OWJJMQOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr#Hs`Hr#HrlHsHs`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071643DV100716431007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OWJJOAOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-12ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr#Hs`Hr#HrlHsHs`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071643DV100716431007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1QTCECTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007COVID_A1 NO Non-Important2021-02-22B2DW= YYPhase 3A@ . . .N. A12-15 YearsNAHr#Hs`Hr#HrlHsHs`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071643DV100716431007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBOGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr#Hs`Hr#HrlHsHs`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071643DV100716431007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBOMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr#Hs`Hr#HrlHsHs`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071643DV100716431007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XMBBOSOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr#Hs`Hr#HrlHsHs`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071643DV100716431007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XMBBOYOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr#Hs`Hr#HrlHsHs`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071644DV100716441007AMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OWJJM3Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAHr;pHrhHr;pHrh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071644DV100716441007AMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OWJJMJOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAHr;pHrhHr;pHrh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071644DV100716441007AMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XTQ026Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr;pHrhHr;pHrh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071645DV100716451007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OWJJKWOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAHr8(HsȄHr8(Hr4Hs~.HsȄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071645DV100716451007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OWJJL2Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAHr8(HsȄHr8(Hr4Hs~.HsȄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071645DV100716451007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBKWOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr8(HsȄHr8(Hr4Hs~.HsȄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071645DV100716451007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBN0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr8(HsȄHr8(Hr4Hs~.HsȄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071645DV100716451007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XMBBNGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr8(HsȄHr8(Hr4Hs~.HsȄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071645DV100716451007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XMBBNMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr8(HsȄHr8(Hr4Hs~.HsȄPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071646DV100716461007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OWJJI1Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAHrC,HsHrC,HrHsPHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071646DV100716461007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OWJJJ1Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAHrC,HsHrC,HrHsPHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071647DV100716471007AMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OWJJG2Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAHrEHrlHrEHrl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071647DV100716471007AMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OWJJHUOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .Y. A12-15 YearsNAHrEHrlHrEHrl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071647DV100716471007AMWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1Z3S3BZVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK8 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrEHrlHrEHrl..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071648DV100716481007AMASIAN DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ON6MQCOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr(dHsji@Hr(dHrHsN¨Hsji@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWuYC4591001C4591001 1007 10071648DV100716481007AMASIAN DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ON6MQIOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr(dHsji@Hr(dHrHsN¨Hsji@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWuYC4591001C4591001 1007 10071649DV100716491007AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ON619EOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHr.Hr)Hr.Hr)..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071649DV100716491007AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ON6M4EOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHr.Hr)Hr.Hr)..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ON6MIHOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ON6MINOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1P1ZHV1Subject was vaccinated despite meeting temporary delay criterion #1 (current febrile illness or other acute illness within 48 hrs before study intervention administration. Includes current symptoms that could represent a potential COVID-19 illness.Investigational ProductVACCINATION 1007V1_DAY1_VAX1_L NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ON6MIOProcedure/Test not performed per protocol Procedures/Tests VACCINATION 1007V1_DAY1_VAX1_L NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X3BCY0Lab performed out of window Laboratory FOLLOW-UP 1007V202_SURVEIL_SWAB|639570773683065NO Non-Important2021-04-26BpDW| YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTN7RRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK8 NO Non-Important2021-04-26BpDW| YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XMBBP4Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XMBBPAOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XMBBPGOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071650DV100716501007AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XMBBPMOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr@LHsHr@LHrHs}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071651DV100716511007AMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ON6MQZOther Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrHr=Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071651DV100716511007AMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ON6MR5Other Informed Consent Informed Consent VACCINATION 1007Consent NO Non-Important2021-01-05ADW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrHr=Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071651DV100716511007AMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XTQ029Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrHr=Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071652DV100716521007AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1WTN7RUVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK8 NO Non-Important2021-04-20BjDWv YYPhase 3A@ . . .N. A12-15 YearsNAHrB,HslHrB,Hr\Hs|HHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071652DV100716521007AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1X3BCY3Lab performed out of window Laboratory FOLLOW-UP 1007V202_SURVEIL_SWAB|640689756662050NO Non-Important2021-04-26BpDW| YYPhase 3A@ . . .N. A12-15 YearsNAHrB,HslHrB,Hr\Hs|HHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071652DV100716521007AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XM5NRVOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrB,HslHrB,Hr\Hs|HHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071652DV100716521007AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XM5NSLOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrB,HslHrB,Hr\Hs|HHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071652DV100716521007AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XM5NSROther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrB,HslHrB,Hr\Hs|HHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071652DV100716521007AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XM5NSXOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrB,HslHrB,Hr\Hs|HHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071652DV100716521007AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YV6XSFVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-06-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrB,HslHrB,Hr\Hs|HHslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071653DV100716531007AMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XTQ02CVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrn<Hr!Hrn<Hr!..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071654DV100716541007AFWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OV1ORANasal swab not collected for the visit where it is required Laboratory VACCINATION 1007V2_VAX2_L NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAHrkHr"HrkHr"..Placebo Placebo .DWYC4591001C4591001 1007 10071654DV100716541007AFWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1QW05STSerology sample not collected Laboratory FOLLOW-UP 1007V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-23B2DW> YYPhase 3A@ . . .N. A12-15 YearsNAHrkHr"HrkHr"..Placebo Placebo .DWYC4591001C4591001 1007 10071654DV100716541007AFWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSYJV7Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrkHr"HrkHr"..Placebo Placebo .DWYC4591001C4591001 1007 10071654DV100716541007AFWHITE DW DW"Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1ZCJ1HFSerology sample not collected Laboratory REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-07-22BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrkHr"HrkHr"..Placebo Placebo .DWYC4591001C4591001 1007 10071655DV100716551007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGLXQIOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr{Hs;hHr{Hr*Hsr<Hs;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071655DV100716551007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXQOOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr{Hs;hHr{Hr*Hsr<Hs;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071655DV100716551007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLXQUOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr{Hs;hHr{Hr*Hsr<Hs;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071655DV100716551007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XGLXR0Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr{Hs;hHr{Hr*Hsr<Hs;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071655DV100716551007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1ZE8TWISerology sample not collected Laboratory OPEN LABEL TREATMENT1007V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr{Hs;hHr{Hr*Hsr<Hs;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071655DV100716551007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z3A9BFSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsOPEN LABEL TREATMENT1007V102_VAX4 NO Non-Important2021-07-02BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr{Hs;hHr{Hr*Hsr<Hs;hPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071656DV100716561007AFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YBEUB2Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK10 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrńHrvHrńHrv..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071658DV100716581007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGLXR6Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs-HrHr9HsrlHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071658DV100716581007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XGLXRCOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs-HrHr9HsrlHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071658DV100716581007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XGLXSWOther Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs-HrHr9HsrlHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071658DV100716581007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XGLXT2Other Informed Consent Informed Consent OPEN LABEL TREATMENT1007Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs-HrHr9HsrlHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071658DV100716581007AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1YGUX98Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL TREATMENT1007COVID_A NO Non-Important2021-06-08BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs-HrHr9HsrlHs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071659DV100716591007AFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1X3BCPSNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1007SSWAB_WEEK4 NO Non-Important2021-03-28BRDW_ YYPhase 3A@ . . .Y. A12-15 YearsNAHr\HrᄐHr\Hrᄐ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071659DV100716591007AFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1YEE5NZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-04-08B]DWj YYPhase 3A@ . . .Y. A12-15 YearsNAHr\HrᄐHr\Hrᄐ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071659DV100716591007AFWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XTQ02FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr\HrᄐHr\Hrᄐ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071660DV100716601007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1X3BCXXNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1007SSWAB_WEEK4 NO Non-Important2021-03-28BRDW_ YYPhase 3A@ . . .N. A12-15 YearsNAHrlHsHrlHrHsq HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071660DV100716601007AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YEE5O3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1007SSWAB_WEEK6 NO Non-Important2021-04-08B]DWj YYPhase 3A@ . . .N. A12-15 YearsNAHrlHsHrlHrHsq HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071661DV100716611007AFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XTQ02IVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007SSWAB_WEEK12 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr xHrhHr xHrh..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1007 10071662DV100716621007AFWHITE DWDW$Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSYJVAReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1007V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr)$Hr|LHr)$Hr|L..Placebo Placebo .DWYC4591001C4591001 1007 10071662DV100716621007AFWHITE DWDW$Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZH2UHGVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1007V4_MONTH6_L NO Non-Important2021-08-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr)$Hr|LHr)$Hr|L..Placebo Placebo .DWYC4591001C4591001 1008 10081751DV100817511008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5EFIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr0Hsn|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081752DV100817521008AMASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WKF774Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK4 NO Non-Important2021-04-19BDWu YYPhase 3A@ . . .N. A12-15 YearsNAHrXHs'HrXHrPHslHs'Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081752DV100817521008AMASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5EJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHs'HrXHrPHslHs'Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081753DV100817531008AMASIAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1WKF777Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK4 NO Non-Important2021-04-19BDWu YYPhase 3A@ . . .Y. A12-15 YearsNAHrXDHrHrXDHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081756DV100817561008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XDA5EMIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-22BDWx YYPhase 3A@ . . .N. A12-15 YearsNAHr<HskHr<Hr0HsQ8HskPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWwYC4591001C4591001 1008 10081756DV100817561008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YL1U1ARevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HskHr<Hr0HsQ8HskPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWwYC4591001C4591001 1008 10081756DV100817561008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YL1U48Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HskHr<Hr0HsQ8HskPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWwYC4591001C4591001 1008 10081757DV100817571008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5FJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr|Hsrm4HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081758DV100817581008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1WTN7S0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-29BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081761DV100817611008AFWHITE DVDW}Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5FMIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-05BxDWg YYPhase 3A@ . . .N. A12-15 YearsNAHr:HsXHr:HrtHs;"HsXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWgYC4591001C4591001 1008 10081763DV100817631008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P9LCCZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-25B2DW! YYPhase 3A@ . . .N. A12-15 YearsNAHrOHsHrOHrr|Hsu$HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081763DV100817631008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1R5SPMOOther Informed Consent Informed Consent FOLLOW-UP 1008Consent NO Non-Important2021-03-12B`DWO YYPhase 3A@ . . .N. A12-15 YearsNAHrOHsHrOHrr|Hsu$HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081764DV100817641008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1P9LCD3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-25B2DW! YYPhase 3A@ . . .Y. A12-15 YearsNAHrNdHr[HHrNdHr[H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081767DV100817671008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5FPIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsϬHrHrHsmO HsϬPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081769DV100817691008AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1R7E1VZVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-23BNDW> YYPhase 3A@ . . .Y. A12-15 YearsNAHrPHrHrPHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWvYC4591001C4591001 1008 10081773DV100817731008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5FSIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr(HshHr(Hr Hsn`HshPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081774DV100817741008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YM02Z7Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-17BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081775DV100817751008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YNZMAZVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1008V102_VAX4 NO Non-Important2021-06-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsHHr<HrHsw HsHPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081780DV100817801008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5HJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr.DHshHr.DHrHsr4|HshPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081788DV100817881008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5HMIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr3HsLHr3Hr HslHsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081790DV100817901008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5HPIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlHs͐HrlHrxHslHs͐Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081793DV100817931008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5KAIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrz\HsHrz\HrLHsm*HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081794DV100817941008AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5KDIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr{HsHr{HrHsm1 HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081796DV100817961008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WNXXE5Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V202_SURVEIL_SWAB|641134295578050NO Non-Important2021-04-13BxDWo YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHruHsnCDHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081796DV100817961008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5KGIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHruHsnCDHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081798DV100817981008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5LNIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrʰHs)HrʰHr}Hsnb4Hs)Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081799DV100817991008AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OCN9STUrine pregnancy test not performed. Laboratory VACCINATION 1008V1_DAY1_VAX1_L NO Non-Important2020-12-15ADV YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr5HHrHr5H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081799DV100817991008AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2A4Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr5HHrHr5H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081799DV100817991008AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZHUT58Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr5HHrHr5H..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081801DV100818011008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZE8TWLSerology sample not collected Laboratory FOLLOW-UP 1008V201_SURVEIL_CONSENT NO Non-Important2021-03-22B`DWY YYPhase 3A@ . . .N. A12-15 YearsNAHr2(HslHr2(HrHsrn`HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081801DV100818011008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5LQIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr2(HslHr2(HrHsrn`HslPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081803DV100818031008AMBLACK OR AFRICAN AMERICAN DVDWkPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5LTIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V102_VAX4 NO Non-Important2021-04-09BrDWk YYPhase 3A@ . . .N. A12-15 YearsNAHr^Hs@SHr^Hr4Hs$Hs@SPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWKYC4591001C4591001 1008 10081804DV100818041008AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5OFIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHreHsHreHrHsm1HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081805DV100818051008AFASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZHUT9RVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-07-01BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrqHr HrqHr ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081805DV100818051008AFASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YXHVRASerology sample not collected Laboratory REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-02BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrqHr HrqHr ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081807DV100818071008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5OIIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrzHs4HrzHr?HsnCHs4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081808DV100818081008AMASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5OLIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr~HsHr~Hr>Hsr3HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081809DV100818091008AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5OOIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrI0HsmOHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081809DV100818091008AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z6G6WHVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1008V103_MONTH1 NO Non-Important2021-07-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrI0HsmOHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081811DV100818111008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OFAVJLOther Informed Consent Informed Consent VACCINATION 1008Consent NO Non-Important2020-12-18ADV YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr6pHrHr6p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081811DV100818111008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1XPVX9KLab performed out of window Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK8 NO Non-Important2021-06-01BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr6pHrHr6p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081811DV100818111008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XSGB0VVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK8 NO Non-Important2021-06-01BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr6pHrHr6p..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081812DV100818121008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5QZIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs$HrHrfHsmHHs$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081817DV100818171008AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PLVAJEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-12B9DW3 YYPhase 3A@ . . .N. A12-15 YearsNAHrHHs HrHHr̠HsnfHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081817DV100818171008AFASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5R2Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHHs HrHHr̠HsnfHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081818DV100818181008AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XT0RCTNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-25BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr(HrcpHr(Hrcp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081819DV100818191008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5R5Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlpHs/HrlpHr_Hss{Hs/Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081821DV100818211008AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1PF862JVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-08B2DW/ YYPhase 3A@ . . .Y. A12-15 YearsNAHruHrͱHruHrͱ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081822DV100818221008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5R8Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrxHsHrxHrb|HsncHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081825DV100818251008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5RBIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs4HrHrMdHsm&Hs4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081826DV100818261008AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YD7IC0Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-05-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr͝|HrHr͝|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081828DV100818281008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1PDX79CVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1008V2_VAX2_L NO Non-Important2021-01-22B!DW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsnHrHrlHsnX\HsnPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081828DV100818281008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5REIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsnHrHrlHsnX\HsnPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081828DV100818281008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Y1PBIBVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1008V102_VAX4 NO Non-Important2021-06-08BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsnHrHrlHsnX\HsnPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081831DV100818311008AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1VISO3TVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008COVID_A1 NO Non-Important2021-04-20BxDWv YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrYHrHrY..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081832DV100818321008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIW26QVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-08-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrʘHr`HrʘHr`..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081833DV100818331008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5RRIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrlHsHrlHr`HsnoHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081836DV100818361008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QTCECWVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008COVID_A1 NO Non-Important2021-02-23B@DW> YYPhase 3A@ . . .N. A12-15 YearsNAHr4HsHr4Hr[(HsnKHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081836DV100818361008AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5RUIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr4HsHr4Hr[(HsnKHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081837DV100818371008AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZMN4EIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr HsHr HrͷDHsuPHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081838DV100818381008AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YBEUBBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr HrͶTHr HrͶT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081838DV100818381008AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1YBEUBEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-05-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr HrͶTHr HrͶT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081838DV100818381008AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YBEUBHVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr HrͶTHr HrͶT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081839DV100818391008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XK42SNLab performed out of window Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-05-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr (HrͩpHr (Hrͩp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081839DV100818391008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1YM02ZEVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-05-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr (HrͩpHr (Hrͩp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081839DV100818391008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YM0301Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK8 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr (HrͩpHr (Hrͩp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081839DV100818391008AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1YM02ZBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr (HrͩpHr (Hrͩp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081840DV100818401008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5RXIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs'HrHr4HsnHs'Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081842DV100818421008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QW7RGHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-19B;DW: YYPhase 3A@ . . .N. A12-15 YearsNAHr HsHr HrWHsu HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081843DV100818431008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YV6XSIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-06-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr$HrHr$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081845DV100818451008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZE8TWOSerology sample not collected Laboratory FOLLOW-UP 1008V201_SURVEIL_CONSENT NO Non-Important2021-04-05BhDWg YYPhase 3A@ . . .N. A12-15 YearsNAHr4Hs3Hr4HrHsrnHs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081845DV100818451008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5S0Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr4Hs3Hr4HrHsrnHs3Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081849DV100818491008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XDA5S3Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr#\Hs Hr#\Hr5xHsnzHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081849DV100818491008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YXG8IVSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsOPEN LABEL TREATMENT1008V102_VAX4 NO Non-Important2021-06-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr#\Hs Hr#\Hr5xHsnzHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081851DV100818511008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5S6Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr2Hs-HHr2Hrь Hss{4Hs-HPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081852DV100818521008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5S9Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr3Hs-Hr3HrэLHss{Hs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081854DV100818541008AMASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z499HSVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr\HrRtHr\HrRt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081861DV100818611008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5SDIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr|HsHr|HrrHsnHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081862DV100818621008AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZHEE05Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-08-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr4HrpHr4Hrp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081863DV100818631008AFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5SGIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr PHsXHr PHrdHsr3PHsXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081864DV100818641008AFASIAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZH2CQMNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK18 NO Non-Important2021-07-24BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr |HrdHr |Hrd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081866DV100818661008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5SJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr8HsPHr8Hr{HsnEHsPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081867DV100818671008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5VYIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr9HsHr9Hr{HsnFHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081868DV100818681008AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZHUT9UVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-10BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr;HrTHr;HrT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081869DV100818691008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5W1Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr>Hsc8Hr>Hr֔HsnIHsc8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081870DV100818701008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1WTN7T0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-09BfDWk YYPhase 3A@ . . .Y. A12-15 YearsNAHrCHrsHrCHrs..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081870DV100818701008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YV6XSLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrCHrsHrCHrs..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081870DV100818701008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZF2K25Other lab deviation Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-03BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrCHrsHrCHrs..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081870DV100818701008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1YV6XT8Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-03BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrCHrsHrCHrs..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081870DV100818701008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1Z499SPVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrCHrsHrCHrs..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081871DV100818711008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QW7RGLVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1008V2_VAX2_L NO Non-Important2021-02-16B1DW7 YYPhase 3A@ . . .N. A12-15 YearsNAHrPHsDHrPHrPHsm2HsDPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081871DV100818711008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDA5W4Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrPHsDHrPHrPHsm2HsDPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081872DV100818721008AMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1UIL7TCSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsOPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-09BeDWk YYPhase 3A@ . . .N. A12-15 YearsNAHrXHsYmHrXHr$Hs@bDHsYmPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1UIL84USubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsOPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-09BeDWk YYPhase 3A@ . . .N. A12-15 YearsNAHrXHsYmHrXHr$Hs@bDHsYmPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XK1TL9Nasal swab collected at a visit where it was not required Laboratory OPEN LABEL TREATMENT1008SSWAB_WEEK8 NO Non-Important2021-04-23BsDWy YYPhase 3A@ . . .N. A12-15 YearsNAHrXHsYmHrXHr$Hs@bDHsYmPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1XK2YZMNasal swab collected at a visit where it was not required Laboratory OPEN LABEL TREATMENT1008SSWAB_WEEK10 NO Non-Important2021-05-02B|DW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHsYmHrXHr$Hs@bDHsYmPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1WTN7SXVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1008SSWAB_WEEK6 NO Non-Important2021-05-02B|DW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHsYmHrXHr$Hs@bDHsYmPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XDAWC5Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-09BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHsYmHrXHr$Hs@bDHsYmPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081872DV100818721008AMWHITE DWDW~Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XK2YZSNasal swab collected at a visit where it was not required Laboratory OPEN LABEL TREATMENT1008SSWAB_WEEK12 NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrXHsYmHrXHr$Hs@bDHsYmPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWiYC4591001C4591001 1008 10081873DV100818731008AFBLACK OR AFRICAN AMERICAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2A7Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-05-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrXHrJHrXHrJ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081873DV100818731008AFBLACK OR AFRICAN AMERICAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZHUT9XVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrXHrJHrXHrJ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081873DV100818731008AFBLACK OR AFRICAN AMERICAN DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZCDLQ3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrXHrJHrXHrJ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081874DV100818741008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2ABNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-05-26BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr_HrHr_Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081874DV100818741008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1XNE0EIVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008COVID_B1 NO Non-Important2021-06-03BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr_HrHr_Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081874DV100818741008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZIM2EKNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr_HrHr_Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081874DV100818741008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1ZHUTBYVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr_HrHr_Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081875DV100818751008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWC8Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`Hs$Hr`HrHsl8Hs$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081875DV100818751008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XNE0FZVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1008COVID_B1 NO Non-Important2021-06-03BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`Hs$Hr`HrHsl8Hs$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081876DV100818761008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1WH6QCHVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK2 NO Non-Important2021-03-17BNDWT YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr%DHrHr%D..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081876DV100818761008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1VIRO0XNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK4 NO Non-Important2021-03-27BXDW^ YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr%DHrHr%D..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081877DV100818771008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCBIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs$HrHr6Hsrm4Hs$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081878DV100818781008AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2EZNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK20 NO Non-Important2021-07-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr8Hr6$Hr8Hr6$..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081879DV100818791008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1V9SUKYNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-03-29BZDW` YYPhase 3A@ . . .N. A12-15 YearsNAHrdHrHrdHr..Placebo Placebo .DWYC4591001C4591001 1008 10081879DV100818791008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1XE4MVBNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK10 NO Non-Important2021-05-02B|DW YYPhase 3A@ . . .N. A12-15 YearsNAHrdHrHrdHr..Placebo Placebo .DWYC4591001C4591001 1008 10081879DV100818791008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XGCGK3Receipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1008V202_SURVEIL_SWAB|643544415756058YES-POP2,YES-POP3Important 2021-05-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrdHrHrdHr..Placebo Placebo .DWYC4591001C4591001 1008 10081879DV100818791008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YBSBMIReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1008V2_VAX2_L YES-POP2,YES-POP3Important 2021-06-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrdHrHrdHr..Placebo Placebo .DWYC4591001C4591001 1008 10081880DV100818801008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCEIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrPHsuHrPHrHssHsuPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081881DV100818811008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCHIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr@HsuHr@HrHssXHsuPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081882DV100818821008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZHEE09Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-08-16BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrXHrَpHrXHrَp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081883DV100818831008AFWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z3S3C2Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK18 NO Non-Important2021-07-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrٍHrHrٍ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081884DV100818841008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1QW7RGOVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1008V2_VAX2_L NO Non-Important2021-02-19B3DW: YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrHsmIHsPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081884DV100818841008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZE8TX1Serology sample not collected Laboratory FOLLOW-UP 1008V201_SURVEIL_CONSENT NO Non-Important2021-03-19BODWV YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrHsmIHsPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081884DV100818841008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCKIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrHsmIHsPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081884DV100818841008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Z499SSVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1008V103_MONTH1 NO Non-Important2021-07-09BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrHsmIHsPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081885DV100818851008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1WTN7T3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-06BaDWh YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrDHrHrD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081885DV100818851008AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZMN4ELVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK10 NO Non-Important2021-05-12BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrDHrHrD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081887DV100818871008AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWCOIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs4HrHrHsmKHs4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081888DV100818881008AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWLDIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs HrHrDHsmJHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081891DV100818911008AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWLGIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs&HrHrނHss{4Hs&Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081892DV100818921008AMAMERICAN INDIAN OR ALASKA NATIVE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WNXXE9Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V202_SURVEIL_SWAB|636898268190060NO Non-Important2021-03-03B;DWF YYPhase 3A@ . . .N. A12-15 YearsNAHr`Hsa8Hr`HrHs|Hsa8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081892DV100818921008AMAMERICAN INDIAN OR ALASKA NATIVE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WNXXECVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008V202_SURVEIL_SWAB|638114927454060NO Non-Important2021-03-22BNDWY YYPhase 3A@ . . .N. A12-15 YearsNAHr`Hsa8Hr`HrHs|Hsa8Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081893DV100818931008AFWHITE DW DW!BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZHUTC1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK20 NO Non-Important2021-07-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081894DV100818941008AFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZE8TX4Serology sample not collected Laboratory FOLLOW-UP 1008V201_SURVEIL_CONSENT NO Non-Important2021-04-06B]DWh YYPhase 3A@ . . .Y. A12-15 YearsNAHr)Hr2Hr)Hr2..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081894DV100818941008AFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2ENNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK8 NO Non-Important2021-06-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr)Hr2Hr)Hr2..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081894DV100818941008AFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZHUTC4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V202_SURVEIL_SWAB|646226852049030NO Non-Important2021-06-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr)Hr2Hr)Hr2..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081894DV100818941008AFWHITE DW DW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1Z8JZL1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-07-17BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr)Hr2Hr)Hr2..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081896DV100818961008AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWLJIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr+HsHr+HrtHsn}HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081897DV100818971008AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2EQNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr<HrߠHr<Hrߠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081897DV100818971008AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZHVGD3Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr<HrߠHr<Hrߠ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081898DV100818981008AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTNENVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-13BcDWo YYPhase 3A@ . . .N. A12-15 YearsNAHr?\HsHr?\HrވHslHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081898DV100818981008AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWQWIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr?\HsHr?\HrވHslHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081899DV100818991008AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTNENYVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 100813-Apr-21 NO Non-Important2021-04-13BcDWo YYPhase 3A@ . . .N. A12-15 YearsNAHr?HsHr?HrމpHslXHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081899DV100818991008AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWQZIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr?HsHr?HrމpHslXHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081900DV100819001008AFWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZHVGD6Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK20 NO Non-Important2021-07-18BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrrHr# HrrHr# ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081902DV100819021008AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P19HPPAssessment of acute reaction for protocol specified timeframe after study intervention administration not performed at the vaccination visits. Procedures/Tests VACCINATION 1008V1_DAY1_VAX1_L NO Non-Important2021-01-05ADW YYPhase 3A@ . . .N. A12-15 YearsNAHrvHs<HrvHrHsmHHs<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081902DV100819021008AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWR3Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrvHs<HrvHrHsmHHs<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081903DV100819031008AMWHITE DW DW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z6VL04Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-07-16BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrxHrHHrxHrH..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081904DV100819041008AMWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWR6Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr|LHsHr|LHrHsm>HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081905DV100819051008AFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2ETNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrň0HrHrň0Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081905DV100819051008AFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZHVGD9Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V202_SURVEIL_SWAB|646303539298030NO Non-Important2021-06-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrň0HrHrň0Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081905DV100819051008AFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1Z6VL07Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK18 NO Non-Important2021-07-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrň0HrHrň0Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081906DV100819061008AFASIAN DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1VM3J5ZNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-18BgDWt YYPhase 3A@ . . .Y. A12-15 YearsNAHrŏ8Hr9Hrŏ8Hr9..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081906DV100819061008AFASIAN DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1Z499SVVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-07-02BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrŏ8Hr9Hrŏ8Hr9..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081907DV100819071008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWR9Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrŔHs*HrŔHr6HHsn$Hs*Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081909DV100819091008AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1TVW3JCNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK2 NO Non-Important2021-03-08B>DWK YYPhase 3A@ . . .N. A12-15 YearsNAHrŖ@HsHrŖ@HruHsu@HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081909DV100819091008AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YV6XTBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1008SSWAB_WEEK8 NO Non-Important2021-05-05BxDW YYPhase 3A@ . . .N. A12-15 YearsNAHrŖ@HsHrŖ@HruHsu@HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081911DV100819111008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWRCIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr⍤HsnDHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081912DV100819121008AMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZH2CTRNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK20 NO Non-Important2021-07-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr4Hr,Hr4Hr,..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081913DV100819131008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWRPIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr̠Hs|Hr̠Hr@Hsr4Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081914DV100819141008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1QW7RL7Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1008V2_VAX2_L NO Non-Important2021-02-12B&DW3 YYPhase 3A@ . . .N. A12-15 YearsNAHrtHsHrtHrZxHsm?HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081914DV100819141008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWRSIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrtHsHrtHrZxHsm?HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081919DV100819191008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OT9IF1Procedure not performed as part of vital signs. Procedures/Tests SCREENING 1008V2_VAX2_L NO Non-Important2020-11-01CDVYNYPhase 3A@ . . .N. A12-15 YearsNAHrHs <HrHrTHsuHs <Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081920DV100819201008AFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1XTRH45Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK12 NO Non-Important2021-06-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrlHrHrlHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081920DV100819201008AFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2EWNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1008SSWAB_WEEK14 NO Non-Important2021-06-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrlHrHrlHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081920DV100819201008AFWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZHVGDCVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-29BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrlHrHrlHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081921DV100819211008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1XDAWRVIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-04-26BnDW| YYPhase 3A@ . . .N. A12-15 YearsNAHr#HHsrw Hr#HHr(HsVlHsrw Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWyYC4591001C4591001 1008 10081921DV100819211008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YLH3L5Revised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr#HHsrw Hr#HHr(HsVlHsrw Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWyYC4591001C4591001 1008 10081921DV100819211008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YLH3MPRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr#HHsrw Hr#HHr(HsVlHsrw Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWyYC4591001C4591001 1008 10081923DV100819231008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWRYIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B~DW YYPhase 3A@ . . .N. A12-15 YearsNAHr-HsHr-HrHsm($HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081924DV100819241008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1QZOQHUSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1008V2_VAX2_L NO Non-Important2021-02-11B#DW2 YYPhase 3A@ . . .N. A12-15 YearsNAHr0Hs Hr0HrlHsnHHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081924DV100819241008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XDAWSBIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr0Hs Hr0HrlHsnHHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081926DV100819261008AFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WOKKODNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1008SSWAB_WEEK6 NO Non-Important2021-04-18BeDWt YYPhase 3A@ . . .N. A12-15 YearsNAHrmHs&THrmHrxHsnHs&TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081926DV100819261008AFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZIZBL2Other Informed Consent Informed Consent OPEN LABEL TREATMENT1008Consent NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrmHs&THrmHrxHsnHs&TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081926DV100819261008AFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1XDAWSEIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrmHs&THrmHrxHsnHs&TPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081930DV100819301008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWSHIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-13B{DW YYPhase 3A@ . . .N. A12-15 YearsNAHr"Hs PHr"Hr8Hsm(Hs PPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081933DV100819331008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWSUIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrNHsHrNHrVHsruHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081934DV100819341008AFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z499SYVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK18 NO Non-Important2021-07-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrWHr HrWHr ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081935DV100819351008AMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1R0XVKGSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1008V2_VAX2_L NO Non-Important2021-02-25B.DW@ YYPhase 3A@ . . .Y. A12-15 YearsNAHr^Hr(Hr^Hr(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWFYC4591001C4591001 1008 10081935DV100819351008AMWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZG7WSKVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008V4_MONTH6_L NO Non-Important2021-08-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr^Hr(Hr^Hr(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWFYC4591001C4591001 1008 10081936DV100819361008AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWSXIncorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B|DW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsOHr`Hr`HsnKHsOPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081937DV100819371008AFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YV6XTEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1008SSWAB_WEEK16 NO Non-Important2021-06-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHreHr \HreHr \..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081938DV100819381008AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWT0Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrgHsHrgHrZHsr4|HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081941DV100819411008AFASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWT3Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B{DW YYPhase 3A@ . . .N. A12-15 YearsNAHrͪHs(pHrͪHrXHsn{Hs(pPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1008 10081942DV100819421008AMASIAN DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XDAWT6Incorrect serology sample volume collected Laboratory OPEN LABEL TREATMENT1008V101_VAX3 NO Non-Important2021-05-14B{DW YYPhase 3A@ . . .N. A12-15 YearsNAHrͫHs'HrͫHrY,Hsn{Hs'Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091204DV100912041009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUC7Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrXxHsHrXxHrqnHsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091205DV100912051009AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZMN4EOVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-18BDWt YYPhase 3A@ . . .Y. A12-15 YearsNAHrX>Hruu HrX>Hruu ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091205DV100912051009AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YGSKODNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1009COVID_A NO Non-Important2021-05-10BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrX>Hruu HrX>Hruu ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091209DV100912091009AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUCAUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-19BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrXuHrr\HrXuHrr\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091212DV100912121009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1O05DG4Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-11-16B DV YYPhase 3A@ . . .N. A12-15 YearsNAHrYcHs'<HrYcHrHswlHs'<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091213DV100912131009AMWHITE DVDWSPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1RVVUQANasal swab collected at a visit where it was not required Laboratory VACCINATION 1009COVID_A NO Non-Important2020-12-02B0DV YYPhase 3A@ . . .N. A12-15 YearsNAHrYkHs l<HrYkHrr Hs8Hs l<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW7YC4591001C4591001 1009 10091213DV100912131009AMWHITE DVDWSPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OEKRU1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009V3_MONTH1_POSTVAX2_L NO Non-Important2020-12-16B>DV YYPhase 3A@ . . .N. A12-15 YearsNAHrYkHs l<HrYkHrr Hs8Hs l<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW7YC4591001C4591001 1009 10091213DV100912131009AMWHITE DVDWSPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1RVVF7LVisit conducted when not required per protocol Visit Schedule FOLLOW-UP 1009COVID_A1 NO Non-Important2021-01-04BQDW YYPhase 3A@ . . .N. A12-15 YearsNAHrYkHs l<HrYkHrr Hs8Hs l<Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW7YC4591001C4591001 1009 10091216DV100912161009AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUCDUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrYHHru-HrYHHru-..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091218DV100912181009AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUCGUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrYtHru.HrYtHru...BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091220DV100912201009AMWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTNEO1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK2 NO Non-Important2021-04-18BDWt YYPhase 3A@ . . .N. A12-15 YearsNAHr]HrvxHr]Hrvx..Placebo Placebo .DWYC4591001C4591001 1009 10091221DV100912211009AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1NR3P0BUrine pregnancy test not performed. Laboratory VACCINATION 1009V1_DAY1_VAX1_L NO Non-Important2020-10-19ADV YYPhase 3A@ . . .Y. A12-15 YearsNAHr]HrvxHr]Hrvx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091221DV100912211009AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1WH6QCLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK2 NO Non-Important2021-04-18BDWt YYPhase 3A@ . . .Y. A12-15 YearsNAHr]HrvxHr]Hrvx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091223DV100912231009AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUD3Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr]HrzHr]Hrz..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091229DV100912291009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1O4AHO2Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-11-23B#DV YYPhase 3A@ . . .N. A12-15 YearsNAHr_Hs}0Hr_Hs#HswHs}0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091229DV100912291009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZK3KGBSubject was vaccinated despite the site being instructed to discontinue further vaccination Investigational ProductFOLLOW-UP 1009Unplanned Vaccination NO Important 2021-03-18BDWU YYPhase 3A@ . . .N. A12-15 YearsNAHr_Hs}0Hr_Hs#HswHs}0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091231DV100912311009AMASIAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUD6Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr_ Hry^Hr_ Hry^..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091233DV100912331009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUD9Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`HsXHr`Hr}eHsHsXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091234DV100912341009AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XSGB0YVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK10 NO Non-Important2021-05-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr`?Hr{Hr`?Hr{..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091237DV100912371009AFWHITE DVDVPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUDCUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests FOLLOW-UP 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr`OtHr}9Hr`OtHr}9..Placebo Placebo .DWYC4591001C4591001 1009 10091240DV100912401009AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUDFUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr`jhHryvpHr`jhHryvp..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091246DV100912461009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OCOVQRSubject received allowable non-study vaccine within 28 days prior to or 28 days after the administration of IP. Concomitant MedicationsVACCINATION 1009V2_VAX2_L NO Non-Important2020-12-07B/DV YYPhase 3A@ . . .N. A12-15 YearsNAHraxHsHraxHrzHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091246DV100912461009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBKUDIUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHraxHsHraxHrzHssHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091272DV100912721009AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZHWDGHVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009V4_MONTH6_L NO Non-Important2021-08-10BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr HrDHr HrD..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091274DV100912741009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS50NSVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs,HrHr<HshHs,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091275DV100912751009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS50NVVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-12-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHHshHrHHrHsHshPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091277DV100912771009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS50NYVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2020-12-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs HrHruHsǬHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091277DV100912771009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YM0304Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK2 NO Non-Important2021-05-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs HrHruHsǬHs Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091280DV100912801009AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUE5Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-06-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr4tHrtHr4tHrt..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091281DV100912811009AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZMN4LFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-05-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrdHrHrd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091283DV100912831009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZE8TX7Serology sample not collected Laboratory FOLLOW-UP 1009V201_SURVEIL_CONSENT NO Non-Important2021-03-30BvDWa YYPhase 3A@ . . .N. A12-15 YearsNAHrpHs`HrpHrHs|Hs`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091283DV100912831009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBKUE8Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-06-21BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrpHs`HrpHrHs|Hs`Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091284DV100912841009AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUEBUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-06-21BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr$HrHr$Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091296DV100912961009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1SSS0N0Potential COVID-19 illness visit not done when required per protocol. Visit Schedule FOLLOW-UP 1009POT_COVID_ILL NO Non-Important2021-02-03B;DW* YYPhase 3A@ . . .N. A12-15 YearsNAHr6|Hs@Hr6|Hr,HsHs@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091304DV100913041009AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z03K9HVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009COVID_A1 NO Non-Important2021-06-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrtHrXHrtHrX..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091312DV100913121009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YV6XU1Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-06-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsXHrHrHs3HsXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091314DV100913141009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZHEE0CVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-08-02BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs,HrHrHsJ`Hs,Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091315DV100913151009AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1WTNEV2Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-26BDW| YYPhase 3A@ . . .Y. A12-15 YearsNAHr(Hr<Hr(Hr<..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091317DV100913171009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUEEUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-06-23BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091319DV100913191009AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1WTNEV5Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-26BDW| YYPhase 3A@ . . .Y. A12-15 YearsNAHr'HrHr'Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091320DV100913201009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PJ91L5Participant met exclusion criterion #01 (participant having other medical or psychiatric condition) Inclusion/Exclusion VACCINATION 1009V1_DAY1_VAX1_L YES-POP2,YES-POP3Important 2020-12-10ADV YYPhase 3A@ . . .N. A12-15 YearsNAHr)HspHr)HrHHs\@HspPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091320DV100913201009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YV6XU4Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-06-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr)HspHr)HrHHs\@HspPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091324DV100913241009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSGB11Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK8 NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrDHs1@HrDHr(HsҚHs1@Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091326DV100913261009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1WTNEV8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-04BsDWf YYPhase 3A@ . . .N. A12-15 YearsNAHrH8HsHrH8HrHHs{HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091326DV100913261009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1WTNEWFVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-04-23BDWy YYPhase 3A@ . . .N. A12-15 YearsNAHrH8HsHrH8HrHHs{HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091326DV100913261009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XSGB14Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrH8HsHrH8HrHHs{HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091326DV100913261009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-200C94RVisit not done Visit Schedule OPEN LABEL TREATMENT1009COVID_A1 NO Non-Important2021-06-09BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrH8HsHrH8HrHHs{HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091326DV100913261009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAp1-1YV6XU7Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-06-25BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrH8HsHrH8HrHHs{HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091326DV100913261009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZJTC3XRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL FOLLOW-UP1009Consent NO Non-Important2021-08-10BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrH8HsHrH8HrHHs{HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091326DV100913261009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZJTC4DRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL FOLLOW-UP1009Consent NO Non-Important2021-08-10BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrH8HsHrH8HrHHs{HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091330DV100913301009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z63DGCSerology sample not collected Laboratory FOLLOW-UP 1009V201_SURVEIL_CONSENT NO Non-Important2021-03-25BiDW\ YYPhase 3A@ . . .N. A12-15 YearsNAHrnHs+HrnHrZXHsxHs+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091330DV100913301009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YY0VDTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK12 NO Non-Important2021-06-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrnHs+HrnHrZXHsxHs+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091330DV100913301009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBKUF1Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-07-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrnHs+HrnHrZXHsxHs+Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091331DV100913311009AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Y55S32Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-06-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrcHrHrc..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091335DV100913351009AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1XDAH01Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1009Potential ReVax Initial Contact NO Non-Important2021-02-22BJDW= YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW=YC4591001C4591001 1009 10091336DV100913361009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XSGB17Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-05-31BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrxHsHrxHrXHs;DHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091338DV100913381009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTC0L3Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-18B$DW YYPhase 3A@ . . .N. A12-15 YearsNAHrfHsI$HrfHrfHsƦHsI$Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091339DV100913391009AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1PDX7EPVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-18B$DW YYPhase 3A@ . . .Y. A12-15 YearsNAHrg$Hra8Hrg$Hra8..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091340DV100913401009AFWHITE DVDW BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YV6XUAVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK14 NO Non-Important2021-06-28BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr,Hr6Hr,Hr6..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091344DV100913441009AMWHITE DVDWZPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBJNERNasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1009COVID_B NO Non-Important2021-07-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs*HrHr(Hs tHs*Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW?YC4591001C4591001 1009 10091347DV100913471009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZH2UNXVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-08-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr4Hs|Hr4HrŒHs-Hs|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091350DV100913501009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZALCUNOther Informed Consent Informed Consent FOLLOW-UP 1009Consent NO Non-Important2021-07-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr|Hsں$Hr|Hr0HsTHsں$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091351DV100913511009AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZE8U0XSerology sample not collected Laboratory FOLLOW-UP 1009V201_SURVEIL_CONSENT NO Non-Important2021-03-22BaDWY YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrŸHrHrŸ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091355DV100913551009AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZD1VOFNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1009SSWAB_WEEK16 NO Non-Important2021-07-08BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr0HrxHr0Hrx..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091356DV100913561009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PKDRMGVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-10B9DW1 YYPhase 3A@ . . .N. A12-15 YearsNAHr;\HsHr;\HrGHsrHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091358DV100913581009AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YV6XUXVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK10 NO Non-Important2021-06-24BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr,LHrvHr,LHrv..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091360DV100913601009AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YBEUBNVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-06-07BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrNHrHrNHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091361DV100913611009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1Z7HG8PVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1009V103_MONTH1 NO Non-Important2021-07-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr^HsHr^HrēHsrHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091362DV100913621009AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1PAQ0TFVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr|HriHr|Hri..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091363DV100913631009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS1Q5BLab performed out of window Laboratory VACCINATION 1009COVID_A NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr|tHspHr|tHr|tHsHspPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091363DV100913631009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1PDX7ESVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-11BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr|tHspHr|tHr|tHsHspPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091363DV100913631009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1PDYN65Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009COVID_A1 NO Non-Important2021-02-09B7DW0 YYPhase 3A@ . . .N. A12-15 YearsNAHr|tHspHr|tHr|tHsHspPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091363DV100913631009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZD1VOINasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1009SSWAB_WEEK12 NO Non-Important2021-07-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr|tHspHr|tHr|tHsHspPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091363DV100913631009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZMN4LIVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-08-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr|tHspHr|tHr|tHsHspPlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091364DV100913641009AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OVT3GIVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-19B"DW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr HrHr ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091364DV100913641009AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1Z6VL0AVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK14 NO Non-Important2021-07-12BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr HrHr ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091365DV100913651009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OVT3GMVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-19B"DW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsvHrHrHs$HsvPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091365DV100913651009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZB90CKOther Informed Consent Informed Consent REPEAT SCREENING 1 1009Consent NO Non-Important2021-07-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsvHrHrHs$HsvPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091365DV100913651009AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZJNOUTVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1009V102_VAX4 NO Non-Important2021-08-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsvHrHrHs$HsvPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091366DV100913661009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1QZSYN3Urine pregnancy test not performed. Laboratory VACCINATION 1009V2_VAX2_L NO Non-Important2021-01-07BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsHr<Hs Hs9HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091366DV100913661009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZK3KGFSubject was vaccinated despite the site being instructed to discontinue further vaccination Investigational ProductFOLLOW-UP 1009Unplanned Vaccination NO Important 2021-02-26BHDWA YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsHr<Hs Hs9HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091366DV100913661009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1RVXPUNUrine pregnancy test not performed. Laboratory FOLLOW-UP 1009Unplanned Vaccination NO Non-Important2021-03-04BNDWG YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsHr<Hs Hs9HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091366DV100913661009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA`1-1XSGB1AVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK10 NO Non-Important2021-05-22BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsHr<Hs Hs9HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091366DV100913661009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1ZJ22XRNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1009SSWAB_WEEK20 NO Non-Important2021-07-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsHr<Hs Hs9HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091366DV100913661009AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZNNH4TRevised ICD not signed at the first subject visits after the revised/approved ICD was available at site Informed Consent OPEN LABEL TREATMENT1009Consent NO Non-Important2021-08-10BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr<HsHr<Hs Hs9HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091380DV100913801009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZIUMM3Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1009V103_MONTH1 NO Non-Important2021-08-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrQDHs3$HrQDHr8Hs+THs3$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091382DV100913821009AFWHITE DW DWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZNKP23Nasal swab not collected for the visit where it is required Laboratory OPEN LABEL FOLLOW-UP1009COVID_B NO Non-Important2021-07-08BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr:HsLHr:Hr|Hsn5pHsLPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091387DV100913871009AMWHITE DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1R1RFRNVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-05B;DWH YYPhase 3A@ . . .Y. A12-15 YearsNAHrżHrLHrżHrL..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091390DV100913901009AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZCT7KEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK16 NO Non-Important2021-07-27BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsdHrHrr8Hs(HsdPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091394DV100913941009AMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1WTNEWIVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-27BoDW} YYPhase 3A@ . . .Y. A12-15 YearsNAHr$8HriHr$8Hri..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091394DV100913941009AMWHITE DWDW#BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZMN4LLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-05-04BvDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr$8HriHr$8Hri..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091395DV100913951009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTNEWLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK4 NO Non-Important2021-04-27BoDW} YYPhase 3A@ . . .N. A12-15 YearsNAHr#Hs-Hr#HrjHs~S$Hs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091395DV100913951009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZKZNV1Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK6 NO Non-Important2021-05-04BvDW YYPhase 3A@ . . .N. A12-15 YearsNAHr#Hs-Hr#HrjHs~S$Hs-Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091396DV100913961009AMWHITE DWDW"BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZH2UO0Potential COVID-19 illness visit not done when required per protocol. Visit Schedule REPEAT SCREENING 1 1009V4_MONTH6_L NO Non-Important2021-08-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr.Hr4Hr.Hr4..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWvYC4591001C4591001 1009 10091399DV100913991009AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZB3T04Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK14 NO Non-Important2021-07-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr@HsϐHr@HrHsHsϐPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091400DV100914001009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1QZ3TPRVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1009V2_VAX2_L NO Non-Important2021-02-12B$DW3 YYPhase 3A@ . . .N. A12-15 YearsNAHrU`HsHrU`HrG@HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091400DV100914001009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1YWWQWWLab performed out of window Laboratory FOLLOW-UP 1009COVID_B NO Non-Important2021-06-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrU`HsHrU`HrG@HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091400DV100914001009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZMN4LOLab performed out of window Laboratory FOLLOW-UP 1009SSWAB_WEEK14 NO Non-Important2021-07-28BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrU`HsHrU`HrG@HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091404DV100914041009AFWHITE DWDW%BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZB3T07Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK10 NO Non-Important2021-07-12BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrȄ|HrHrȄ|Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1009 10091406DV100914061009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1SSS10VPotential COVID-19 illness visit not done when required per protocol. Visit Schedule VACCINATION 1009POT_COVID_ILL NO Non-Important2021-01-25BDW! YYPhase 3A@ . . .N. A12-15 YearsNAHrȘhHszPHrȘhHrHsdHszPPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091407DV100914071009AFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZHVLXGVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK2 NO Non-Important2021-05-03BqDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrB$HrTHrB$HrT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091407DV100914071009AFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1Z499TBVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK6 NO Non-Important2021-06-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrB$HrTHrB$HrT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091407DV100914071009AFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZD1VPFNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-07-12BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrB$HrTHrB$HrT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091407DV100914071009AFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZD1VPINasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1009SSWAB_WEEK10 NO Non-Important2021-07-31BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrB$HrTHrB$HrT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091407DV100914071009AFASIAN DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1ZHWDGKVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-08-03BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrB$HrTHrB$HrT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091408DV100914081009AFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1YK0FBJNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1009COVID_A NO Non-Important2021-06-24BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr̄xHrHr̄xHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091408DV100914081009AFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZB3T0AVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK10 NO Non-Important2021-07-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr̄xHrHr̄xHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091409DV100914091009AFWHITE DWDW)BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZB3T0DVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK10 NO Non-Important2021-07-20BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr̄Hr\Hr̄Hr\..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091410DV100914101009AFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1PAG7MTVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1009V2_VAX2_L NO Non-Important2021-02-01BDW( YYPhase 3A@ . . .Y. A12-15 YearsNAHrgHr&HrgHr&..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091410DV100914101009AFWHITE DWDW(BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1YBECDLVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1009SSWAB_WEEK8 NO Non-Important2021-06-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrgHr&HrgHr&..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091412DV100914121009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1T8K11VVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-15B?DWR YYPhase 3A@ . . .N. A12-15 YearsNAHrͷHsHrͷHrLHsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091412DV100914121009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZE8U10Serology sample not collected Laboratory FOLLOW-UP 1009V201_SURVEIL_CONSENT NO Non-Important2021-03-29BMDW` YYPhase 3A@ . . .N. A12-15 YearsNAHrͷHsHrͷHrLHsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091412DV100914121009AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YY0VDWVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1009SSWAB_WEEK10 NO Non-Important2021-07-02BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrͷHsHrͷHrLHsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1009 10091413DV100914131009AFWHITE DWDW*BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1Z9VPFJNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1009COVID_A NO Non-Important2021-07-27BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrͼHrİHrͼHrİ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131821DV101318211013AMBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1P02XECICD signed by unauthorized site personnel Informed Consent FOLLOW-UP 1013Consent NO Non-Important2021-01-27B;DW# YYPhase 3A@ . . .Y. A12-15 YearsNAHrHr|HrHr|..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131823DV101318231013AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA125453201IP documentation error IP preparation form errors Investigational ProductVACCINATION 1013Vax 1 NO Non-Important2020-12-01ADV YYPhase 3A@ . . .N. A12-15 YearsNAHr6HsXHr6HrHsHsXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131823DV101318231013AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZJQFESSite staff training missing/incomplete Other OPEN LABEL FOLLOW-UP1013V103_MONTH1 NO Non-Important2021-08-12BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr6HsXHr6HrHsHsXPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131824DV101318241013AFBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OTC3LSSerology sample not collected Laboratory FOLLOW-UP 1013V201_SURVEIL_CONSENT NO Non-Important2021-01-19B2DW YYPhase 3A@ . . .Y. A12-15 YearsNAHr7HrHr7Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131828DV101318281013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OI3QA0Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-30BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrdHrHrdHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131828DV101318281013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1Y55S3FVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-06-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrdHrHrdHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131830DV101318301013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTC5ONVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-23BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrfHrWHrfHrW..Placebo Placebo ..YC4591001C4591001 1013 10131830DV101318301013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1OT48B1Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-18B0DW YYPhase 3A@ . . .N. A12-15 YearsNAHrfHrWHrfHrW..Placebo Placebo ..YC4591001C4591001 1013 10131830DV101318301013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1PDYT7DVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-18B0DW YYPhase 3A@ . . .N. A12-15 YearsNAHrfHrWHrfHrW..Placebo Placebo ..YC4591001C4591001 1013 10131830DV101318301013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PO9518Serology sample not collected Laboratory FOLLOW-UP 1013V201_SURVEIL_CONSENT NO Non-Important2021-01-28B:DW$ YYPhase 3A@ . . .N. A12-15 YearsNAHrfHrWHrfHrW..Placebo Placebo ..YC4591001C4591001 1013 10131830DV101318301013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZMNWARVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-22BDWx YYPhase 3A@ . . .N. A12-15 YearsNAHrfHrWHrfHrW..Placebo Placebo ..YC4591001C4591001 1013 10131835DV101318351013AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTBW9SVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV YYPhase 3A@ . . .N. A12-15 YearsNAHrHs(HrHrHs~rHs(Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131839DV101318391013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1P6MT44Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-19B1DW YYPhase 3A@ . . .N. A12-15 YearsNAHrHrP HrHrP ..Placebo Placebo .DWYC4591001C4591001 1013 10131839DV101318391013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZA0E4VReceipt of any other nonstudy coronavirus vaccine at any time prior to or during the study. Concomitant MedicationsREPEAT SCREENING 1 1013V2_VAX2_L YES-POP2,YES-POP3Important 2021-07-02BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHrP HrHrP ..Placebo Placebo .DWYC4591001C4591001 1013 10131839DV101318391013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1Z6W3C1Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-07-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHrP HrHrP ..Placebo Placebo .DWYC4591001C4591001 1013 10131841DV101318411013AFBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1QZCEMEProcedure/Test not performed per protocol Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV YYPhase 3A@ . . .Y. A12-15 YearsNAHr8HrHr8Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131841DV101318411013AFBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OTBW9VVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV YYPhase 3A@ . . .Y. A12-15 YearsNAHr8HrHr8Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131842DV101318421013AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OTBW9YVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrLHsgHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131842DV101318421013AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTC5OZVaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-22BDV YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrLHsgHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131842DV101318421013AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WTQAQPVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-05B}DWg YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrLHsgHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131842DV101318421013AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1YM00WRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK12 NO Non-Important2021-04-14BDWp YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrLHsgHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131842DV101318421013AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1ZB3T13Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1013V102_VAX4 NO Non-Important2021-07-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHrLHsgHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131843DV101318431013AMBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1PDYT7GVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-27B9DW# YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131843DV101318431013AMBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1YNZMB5Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-14BDWp YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131843DV101318431013AMBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAAP1-1YNZMB8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK14 NO Non-Important2021-05-06BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131843DV101318431013AMBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZF2K28Nasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1013SSWAB_WEEK18 NO Non-Important2021-06-02BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131843DV101318431013AMBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZF2K6RNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1013SSWAB_WEEK20 NO Non-Important2021-06-16BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131843DV101318431013AMBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA`1-1Z6W3C4Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-07-15BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131844DV101318441013AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PDYTCTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-27B9DW# YYPhase 3A@ . . .N. A12-15 YearsNAHrHs\HrHr`HsHs\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131844DV101318441013AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1YV6XV0Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK14 NO Non-Important2021-05-06BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs\HrHr`HsHs\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131844DV101318441013AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1YV6XV3Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK16 NO Non-Important2021-05-14BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs\HrHr`HsHs\Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131845DV101318451013AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1OTBWA1Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHdHrHrHd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131845DV101318451013AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1QZCEMIProcedure/Test not performed per protocol Procedures/Tests FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-01-21B2DW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHdHrHrHd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131845DV101318451013AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1WTQAQSVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-03-22BnDWY YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHdHrHrHd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131845DV101318451013AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1ZMNWAUVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK12 NO Non-Important2021-04-29BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHdHrHrHd..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131850DV101318501013AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1OTC5P5Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2020-12-23BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrXHrHrX..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131850DV101318501013AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1WNXXF8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V202_SURVEIL_SWAB|637164238669060NO Non-Important2021-02-23BSDW> YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrXHrHrX..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131850DV101318501013AFWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1YNZMBBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-05-04BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrXHrHrX..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131851DV101318511013AFMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZH10SYVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1013V102_VAX4 NO Non-Important2021-07-26BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr4HsμHr4HrHsHsμPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131851DV101318511013AFMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZSWS68Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL FOLLOW-UP1013V103_MONTH1 NO Non-Important2021-08-31CDW YYPhase 3A@ . . .N. A12-15 YearsNAHr4HsμHr4HrHsHsμPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131856DV101318561013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1PLVATBVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-08B>DW/ YYPhase 3A@ . . .N. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1013 10131858DV101318581013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WTQAQVVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-03-31BqDWb YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr4pHss٨HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131858DV101318581013AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1Z6G6WZVisit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1013V102_VAX4 NO Non-Important2021-06-15BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHsHrHr4pHss٨HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131859DV101318591013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2F2Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-04-03BtDWe YYPhase 3A@ . . .Y. A12-15 YearsNAHr0HrHr0Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131859DV101318591013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZIM2G9Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-21BDWw YYPhase 3A@ . . .Y. A12-15 YearsNAHr0HrHr0Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131859DV101318591013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1ZIM2GCNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK12 NO Non-Important2021-05-09BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr0HrHr0Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131859DV101318591013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-201SLGJVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK14 NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr0HrHr0Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131861DV101318611013AMBLACK OR AFRICAN AMERICAN DVDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1OS50V9Visit performed outside of protocol specified window. Visit Schedule VACCINATION 1013V2_VAX2_L NO Non-Important2021-01-04BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr8HrHr8..Placebo Placebo .DWYC4591001C4591001 1013 10131861DV101318611013AMBLACK OR AFRICAN AMERICAN DVDW Placebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZNJA6OVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-08-25C0DW YYPhase 3A@ . . .N. A12-15 YearsNAHrHr8HrHr8..Placebo Placebo .DWYC4591001C4591001 1013 10131865DV101318651013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2GFNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-04-11BwDWm YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrHr=Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131865DV101318651013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZHVRQTVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-28BDW~ YYPhase 3A@ . . .Y. A12-15 YearsNAHr=HrHr=Hr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131866DV101318661013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIM2GSNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-04-11BwDWm YYPhase 3A@ . . .Y. A12-15 YearsNAHr=0HrԘHr=0HrԘ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131866DV101318661013AMWHITE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZHVRQXVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-04-28BDW~ YYPhase 3A@ . . .Y. A12-15 YearsNAHr=0HrԘHr=0HrԘ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131867DV101318671013AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1OTBWA7Vaccination diary not completed at all during required 7-day post vaccination period. Procedures/Tests VACCINATION 1013V2_VAX2_L NO Non-Important2021-01-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrG@HsHrG@HrĂHs;HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131867DV101318671013AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WNXXFLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V202_SURVEIL_SWAB|637152332007060NO Non-Important2021-03-10BTDWM YYPhase 3A@ . . .N. A12-15 YearsNAHrG@HsHrG@HrĂHs;HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131867DV101318671013AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1V8LW61Lab performed out of window Laboratory FOLLOW-UP 1013COVID_A NO Non-Important2021-03-16BZDWS YYPhase 3A@ . . .N. A12-15 YearsNAHrG@HsHrG@HrĂHs;HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131867DV101318671013AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA@1-1Z3S3C8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK10 NO Non-Important2021-05-05BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrG@HsHrG@HrĂHs;HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131867DV101318671013AMBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAAP1-1YY0VE2Visit performed outside of protocol specified window. Visit Schedule OPEN LABEL TREATMENT1013V102_VAX4 NO Non-Important2021-06-30BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrG@HsHrG@HrĂHs;HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131868DV101318681013AFMULTIPLE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126429301IP documentation error IP preparation form errors Investigational ProductVACCINATION 1013Vax 1 NO Non-Important2020-12-21ADV YYPhase 3A@ . . .N. A12-15 YearsNAHrxHrͯHrxHrͯ..Placebo Placebo ..YC4591001C4591001 1013 10131869DV101318691013AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PG5YQ1Participant randomized into incorrect age stratum in Impala Randomization VACCINATION 1013V1_DAY1_VAX1 NO Non-Important2020-12-21ADV YYPhase 3A@ . . .N. A12-15 YearsNAHrHrDHrHrD..Placebo Placebo .DWYC4591001C4591001 1013 10131870DV101318701013AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA126429501IP documentation error IP preparation form errors Investigational ProductVACCINATION 1013Vax 1 NO Non-Important2020-12-21ADV YYPhase 3A@ . . .N. A12-15 YearsNAHrHrHrHr..Placebo Placebo ..YC4591001C4591001 1013 10131872DV101318721013AMMULTIPLE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA126429401IP documentation error IP preparation form errors Investigational ProductVACCINATION 1013Vax 1 NO Non-Important2020-12-21ADV YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrlTHrHrlT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131872DV101318721013AMMULTIPLE DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1SST1U8Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013COVID_A1 NO Non-Important2021-03-17BWDWT YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrlTHrHrlT..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131873DV101318731013AFASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1PF862OVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-03B,DW* YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1013 10131873DV101318731013AFASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZF2K6UNasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK22 NO Non-Important2021-07-16BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1013 10131873DV101318731013AFASIAN DVDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZHJ099Nasal swab not collected for the visit where it is required Laboratory FOLLOW-UP 1013SSWAB_WEEK24 NO Non-Important2021-07-18BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrHrHrHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1013 10131874DV101318741013AMASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PF862RVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-02-03B,DW* YYPhase 3A@ . . .N. A12-15 YearsNAHrڈHs4HrڈHr`HsHs4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131874DV101318741013AMASIAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZMNWCLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK14 NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrڈHs4HrڈHr`HsHs4Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131877DV101318771013AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA126525801IP documentation error IP preparation form errors Investigational ProductVACCINATION 1013Vax 2 NO Non-Important2021-01-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr HHrHr HHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131877DV101318771013AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1R163EXVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V3_MONTH1_POSTVAX2_L NO Non-Important2021-03-01BEDWD YYPhase 3A@ . . .Y. A12-15 YearsNAHr HHrHr HHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131877DV101318771013AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1ZF2K6XNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1013SSWAB_WEEK18 NO Non-Important2021-07-05BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr HHrHr HHr..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131878DV101318781013AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZMNWCOVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK8 NO Non-Important2021-04-22ByDWx YYPhase 3A@ . . .N. A12-15 YearsNAHrPHr(HrPHr(..Placebo Placebo .DWYC4591001C4591001 1013 10131878DV101318781013AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XE9KW3Potential COVID-19 illness visit not done when required per protocol. Visit Schedule REPEAT SCREENING 1 1013Potential COVID illness visit NO Non-Important2021-05-19BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrPHr(HrPHr(..Placebo Placebo .DWYC4591001C4591001 1013 10131880DV101318801013AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1WNXXFOVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK4 NO Non-Important2021-03-03BGDWF YYPhase 3A@ . . .Y. A12-15 YearsNAHrDHrr0HrDHrr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131880DV101318801013AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA01-1WTQAQYVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK6 NO Non-Important2021-03-22BZDWY YYPhase 3A@ . . .Y. A12-15 YearsNAHrDHrr0HrDHrr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131880DV101318801013AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZAYZKBNasal swab not collected for the visit where it is required Laboratory REPEAT SCREENING 1 1013SSWAB_WEEK16 NO Non-Important2021-05-31BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrDHrr0HrDHrr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131880DV101318801013AMWHITE DWDWBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA@1-1YNZMBEVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013SSWAB_WEEK18 NO Non-Important2021-06-14BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrDHrr0HrDHrr0..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131882DV101318821013AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1WNXXFRVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013V202_SURVEIL_SWAB|637066170801060NO Non-Important2021-02-23B8DW> YYPhase 3A@ . . .N. A12-15 YearsNAHrTHs>tHrTHrHsr|pHs>tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131882DV101318821013AMWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WTQARLVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK6 NO Non-Important2021-03-03B@DWF YYPhase 3A@ . . .N. A12-15 YearsNAHrTHs>tHrTHrHsr|pHs>tPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131883DV101318831013AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZKZNV5Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1013SSWAB_WEEK6 NO Non-Important2021-04-21BpDWw YYPhase 3A@ . . .N. A12-15 YearsNAHrHs0$HrHr٤xHsvHs0$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131883DV101318831013AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1XA31YTUrine pregnancy test not performed. Laboratory OPEN LABEL TREATMENT1013V101_VAX3 NO Non-Important2021-05-20BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrHs0$HrHr٤xHsvHs0$Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131884DV101318841013AFASIAN DWDW$BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZIUMM7Visit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1013V4_MONTH6_L NO Non-Important2021-08-18BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrLHr߬HrLHr߬..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1013 10131885DV101318851013AFWHITE DWDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA127000101IP documentation error - IRT Confirmation Report Error Investigational ProductVACCINATION 1013Vax 2 NO Non-Important2021-01-26BDW" YYPhase 3A@ . . .N. A12-15 YearsNAHrxHsHrxHr3HsHsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161307DV101613071016AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1WNXXFXVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016V202_SURVEIL_SWAB|635942664602060NO Non-Important2021-02-25BDW@ YYPhase 3A@ . . .N. A12-15 YearsNAHrX5xHs0HrX5xHrrxHstHs0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161307DV101613071016AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUF7Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrX5xHs0HrX5xHrrxHstHs0Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161308DV101613081016AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUGYUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrX6HsHrX6HrqLHs~HsPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161310DV101613101016AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUH1Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrX]HrrjHrX]Hrrj..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161311DV101613111016AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1WZ8A6TVisit performed outside of protocol specified window. Visit Schedule REPEAT SCREENING 1 1016COVID_B1 NO Non-Important2021-05-11BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrXbHrq_HrXbHrq_..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW@YC4591001C4591001 1016 10161314DV101613141016AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA 1-1WH6QX9Visit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK2 NO Non-Important2021-02-24BDW? YYPhase 3A@ . . .Y. A12-15 YearsNAHrYwHrs(HrYwHrs(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1016 10161314DV101613141016AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUH4Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-26BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHrYwHrs(HrYwHrs(..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) ..YC4591001C4591001 1016 10161315DV101613151016AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1PFGQHRLab performed out of window Laboratory FOLLOW-UP 1016V202_SURVEIL_SWAB|634578737276080NO Non-Important2021-02-09BuDW0 YYPhase 3A@ . . .N. A12-15 YearsNAHrY,HsڨHrY,HruTHsvl@HsڨPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161315DV101613151016AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA01-1WH6QXMVisit performed outside of protocol specified window. Visit Schedule FOLLOW-UP 1016SSWAB_WEEK2 NO Non-Important2021-02-09BuDW0 YYPhase 3A@ . . .N. A12-15 YearsNAHrY,HsڨHrY,HruTHsvl@HsڨPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161315DV101613151016AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA 1-1ZBKUI1Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-17BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrY,HsڨHrY,HruTHsvl@HsڨPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161316DV101613161016AMWHITE DVDWSPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1O4N1URVisit performed outside of protocol specified window. Visit Schedule VACCINATION 1016V2_VAX2_L NO Non-Important2020-11-13BDV YYPhase 3A@ . . .N. A12-15 YearsNAHrYHHs HrYHHrYHHslHs Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DW>YC4591001C4591001 1016 10161318DV101613181016AMWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUI4Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrYHs*HrYHrrHs#Hs*Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161319DV101613191016AFWHITE DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUI7Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-18BDW YYPhase 3A@ . . .N. A12-15 YearsNAHrY\Hsi|HrY\HrrHs}$Hsi|Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161320DV101613201016AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUIAUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-17BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr` Hry Hr` Hry ..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161322DV101613221016AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUIXUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr]u`HryHr]u`Hry..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161323DV101613231016AFBLACK OR AFRICAN AMERICAN DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUJ0Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr]PHry"Hr]PHry"..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161324DV101613241016AFBLACK OR AFRICAN AMERICAN DVDWPlacebo PLACEBO Placebo PLACEBO Placebo Placebo AA12-15 YearsAA1-1ZBKUJ3Unblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .N. A12-15 YearsNAHr]HsQHr]Hry#HspHsQPlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161325DV101613251016AFWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUJGUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol Procedures/Tests REPEAT SCREENING 1 1016Potential ReVax Initial Contact NO Non-Important2021-05-13BDW YYPhase 3A@ . . .Y. A12-15 YearsNAHr]HrzHr]Hrz..BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .DWYC4591001C4591001 1016 10161326DV101613261016AMWHITE DVDVBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)BNT162b2 Phase 2/3 (30 mcg)AA12-15 YearsAA1-1ZBKUJJUnblinding procedure for identification of participants to transition from placebo to active not conducted per protocol